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EXECUTIVE SUMMARY 
 
Cancer Incidence and Mortality in Massachusetts, 2010-2014: Statewide Report presents cancer 
incidence and mortality data for the Commonwealth from 2010 through 2014. The report includes 
numbers and rates for 24 types of cancer, information on age-specific patterns, an examination of 
patterns by race/ethnicity, and a comparison of Massachusetts and national cancer rates. A special 
section on hepatitis B/hepatitis C-related cancers is also included.  Data are provided on invasive 
cancers only with the exceptions of urinary bladder (which includes in situ and invasive cancers 
combined) and in situ breast cancer. 
 
All counts and average annual age-adjusted rates presented in this Executive Summary are 
for the period 2010-2014 and are for Massachusetts residents, unless otherwise stated.   
 
OVERALL: 
 
 Total number of new cases – 182,288, an average of 36,458 annually 
 Total number of cancer deaths – 63,671, an average of 12,734 annually 
 Incidence rate (age-adjusted) for all cancers combined for total population – 471.1 per 
100,000 persons 
 Mortality rate (age-adjusted) for all cancer deaths combined for total population – 157.8 
per 100,000 persons. 
 
MOST COMMONLY DIAGNOSED CANCERS & CANCER DEATH CAUSES BY SEX: 
 
Incidence (newly diagnosed cases) 
 Males – prostate cancer accounted for 24.2% of all newly diagnosed cancers among males 
 Females – invasive breast cancer accounted for 29.8% of all newly diagnosed cancers 
among females. 
 
Mortality (cancer deaths) 
 Males – cancer of the bronchus and lung accounted for 26.5% of all cancer deaths among 
males 
 Females – cancer of the bronchus and lung also accounted for 26.5% of all cancer deaths 
among females.  
 
TRENDS 2010-2014: 
 
Statistically Significant Incidence Trends – Males 
 All cancers combined decreased 3.2% per year. 
 Kidney and Renal Pelvis cancer increased 4.3% per year.  
 Prostate cancer decreased by 11.1% per year. 
 
Statistically Significant Mortality Trends – Males 
 All cancers deaths combined decreased 2.0% per year. 
 Bronchus and lung cancer decreased 1.4% per year. 
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 Breast cancer increased 23.1% per year.  (Note:  While this is a statistically significant 
increase, there were 64 deaths from 2010-2014 and the mortality rate increased from 0.2 to 
0.4/100,000.  With such small numbers even an increase of a few cases can result in a 
significant trend.  The rates were comparable to national rates as well.) 
 Kidney and renal pelvis cancer increased 10.4% per year. 
 
Statistically Significant Incidence Trends – Females 
 Bronchus and lung cancer decreased 1.4% per year. 
 Colon and rectum cancer decreased 2.4% per year. 
 Melanoma of skin cancer decreased 4.6% per year. 
 Pancreatic cancer increased 3.0% per year. 
 
Statistically Significant Mortality Trends – Females 
 All cancers deaths combined decreased 1.5% per year. 
 Bronchus and lung cancer decreased 1.0% per year. 
 Hodgkin Lymphoma decreased 22.9% per year (Note: As with male breast cancer 
mortality, there were 44 deaths from 2010-2014 and the mortality rate decreased from 0.3 
to 0.1/100,000.  The rates were comparable to national rates as well.) 
 
RATES BY RACE/ETHNICITY: (Unless otherwise noted, the term ‘racial/ethnic groups’ in this 
report refers to white non-Hispanic, black non-Hispanic, Asian non-Hispanic and Hispanic). 
 
Males Incidence 
 Black, non-Hispanic males had the highest total age-adjusted incidence rates, significantly 
higher than those of all other racial/ethnic groups. 
 Cancers of prostate, bronchus and lung, and colon/rectum were the leading cancer types in 
each racial/ethnic group. 
 White, non-Hispanic males had significantly higher rates of cancers of the brain and other 
nervous system, esophagus, leukemia, and urinary bladder when compared to all other 
race/ethnic groups. 
 Black, non-Hispanic males had significantly higher rates of multiple myeloma and prostate 
cancer when compared to all other race/ethnic groups. 
 Asian, non-Hispanic males had significantly higher rates of liver and intrahepatic bile duct 
cancer when compared to white, non-Hispanic and black, non-Hispanic males. 
Males Mortality 
 Black, non-Hispanic males had the highest total cancer mortality rate, significantly higher 
compared to all other racial/ethnic groups. 
 Cancer of the bronchus and lung was the leading cause of cancer death for each 
racial/ethnic group. White and black, non-Hispanics had significantly elevated rates 
compared to the other two racial/ethnic groups. 
 The mortality rate for prostate cancer and for multiple myeloma was significantly elevated 
among black, non-Hispanic males compared to the other racial/ethnic groups.   
 The mortality rate for liver and intrahepatic cancer was significantly elevated among Asian, 
non-Hispanics compared to the other racial/ethnic groups. 
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Females Incidence 
 White, non-Hispanic females had the highest total age-adjusted incidence rates, 
significantly higher than those of all other racial/ethnic groups. 
 Breast cancer was the most commonly diagnosed cancer for each racial/ethnic group. 
 The second most common cancer diagnosed was bronchus and lung for each racial/ethnic 
group. 
 Compared to all other racial/ethnic groups, white, non-Hispanic females had significantly 
higher rates of the following cancer types:  invasive breast, bronchus and lung, uterus, 
ovary, and urinary bladder. 
 Black, non-Hispanic females had significantly higher rates of multiple myeloma compared 
to all other racial/ethnic groups. 
 Black, non-Hispanic and Hispanic females had significantly higher rates of cervical cancer 
compared to white, non-Hispanic females, but not compared to Asian, non-Hispanic 
females. 
 Asian, non-Hispanic females had significantly higher liver and intrahepatic bile duct cancer 
rates compared to white non-Hispanics and black non-Hispanics, but not compared to 
Hispanics. 
 
Females Mortality 
 Black and white, non-Hispanic females had the highest total cancer mortality rates, 
significantly higher than for Asian, non-Hispanic and Hispanic females. 
 Cancer of the bronchus and lung was the leading cause of cancer death among all 
racial/ethnic groups. White, non-Hispanic females had significantly elevated rates 
compared to the other racial/ethnic groups. 
 Black, non-Hispanic females had significantly elevated uterine cancer mortality rates when 
compared to the other racial/ethnic groups.  Their breast cancer mortality rate was 
significantly elevated compared to that of Asian, non-Hispanic and Hispanic females, but 
was not significantly elevated compared to white, non-Hispanic females.  
 
MASSACHUSETTS VS. NATIONAL RATES 
 
Males and Females Incidence 
 
Overall age-adjusted cancer incidence rates in Massachusetts were significantly lower than 
national rates for males, and were significantly higher than national rates for females.  Among the 
cancers significantly elevated for females were invasive and in situ breast, bronchus and lung, 
uterine, esophageal, melanoma of skin, oral cavity and pharynx, thyroid, and urinary bladder.  
Among those cancers significantly elevated for males were esophagus, liver and intrahepatic bile 
ducts, testicular, thyroid and urinary bladder.  Incidence rates that were significantly lower 
compared to the U.S. among females were cervix uteri, colon and rectum, and kidney and renal 
pelvis, while among males the cancer types included bronchus and lung, colon and rectum, larynx, 
and prostate. 
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Males and Females Mortality 
 
Overall age-adjusted cancer mortality rates in Massachusetts were significantly lower from 
national rates for both males and females.  However, there were some individual cancers that had 
significantly elevated mortality rates compared to the U.S.  These include male esophagus and 
female urinary bladder.  Those cancers that were significantly lower compared to the U.S. included 
breast, cervix uteri, colon/rectum, and kidney and renal pelvis among females, and bronchus and 
lung, colon/rectum, kidney and renal pelvis, multiple myeloma, non-Hodgkin lymphoma, prostate, 
and testis among males.    
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INTRODUCTION 
 
The Massachusetts Cancer Registry (MCR) collects reports of newly diagnosed cases of cancer and 
routinely compiles summaries of cancer incidence and mortality data. This report, Cancer Incidence and 
Mortality in Massachusetts, 2010-2014: Statewide Report is produced annually with the most recently 
available statewide data. Another report, Cancer Incidence in Massachusetts: City and Town Supplement, is 
also produced annually and contains information for the 351 cities and towns in Massachusetts. Electronic 
versions of these reports may be found on the internet at www.mass.gov/dph/mcr.  
 
Overall Content 
 
This report: 
 
 Provides statewide information on cancer incidence and mortality in Massachusetts for twenty-four 
types of cancer and for all cancers combined for 2010 through 2014;* 
 
 Provides detailed information on the most commonly occurring types of cancer for 2010 through 
2014; 
 
 Examines cancer incidence patterns by age, sex, and race/ethnicity; 
 
 Reviews Massachusetts cancer incidence and mortality trends for 2010 through 2014;  
 
 Compares Massachusetts incidence and mortality data with respective national data; and 
 
 Features a special section on the epidemiology of hepatitis B/C-related cancers. 
 
The report is organized into the following sections: 
 
 SPECIAL OVERVIEW which provides more detailed information on a specific topic of interest 
in Massachusetts.  This report has a special overview of the epidemiology of hepatitis B/C-related 
cancers. 
 
 FIGURES & TABLES which present cancer incidence and mortality data for 24 types of cancer 
for 2010-2014. There are 6 figures and 24 tables in this section with breakdowns by sex, 
race/ethnicity, year, age group, state and national comparisons, and cancer type. 
 
 APPENDICES which provide information supplemental to this report, including a listing of codes 
used to prepare the report, information on population and rate changes, and population estimates. 
 
 REFERENCES 
 
*The Massachusetts incidence data in this report include only invasive cancers for 22 of the 24 types of 
cancer. Cancer of the urinary bladder includes both in situ and invasive cases. Cancer of the breast in situ 
is presented as a separate category but is not included in the “all sites combined” data. 
 
Note: For more detailed information on the methods of the Massachusetts Cancer Registry, please refer 
to Cancer Incidence and Mortality in Massachusetts 2006-2010: Statewide Report (1).  For national 
trends, please refer to the Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring 
Survival (2).  
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The Epidemiology of Cancer and Benign Brain Tumors among Massachusetts Residents 
with Hepatitis B or Hepatitis C from 2002-2012 
INTRODUCTION 
Hepatitis B is an infection of the liver caused by the hepatitis B virus (HBV).  Of those infected with  HBV 
10% may progress to a chronic infection and can pass the virus to others via sexual contact and contact with 
infected blood, including needle sharing to inject drugs.  Through maternal transmission, pregnant women 
can pass the infection to their babies at birth.1   Hepatitis C is an infection of the liver caused by the hepatitis 
C virus (HCV).  Unlike HBV infection, most people who get infected with HCV progress to a chronic 
infection.  Risk factors for HCV transmission include receiving infected blood products before widespread 
screening in 1992, needle sharing to inject drugs, and maternal-fetal transmission.  Sexual transmission of 
HCV is possible, but rare.  Sexual transmission is increased by having a sexually transmitted disease or HIV 
infection, sex with multiple partners, or rough sex.2 
Liver inflammation from chronic HBV or HCV infection can cause scarring of the liver or cirrhosis, which 
in turn can lead to liver cancer. The association of liver cancer and HBV was first proposed in 1972, shortly 
after the discovery of HBV.3   The association of liver cancer and HCV was established soon after the 
discovery of HCV in 1989.4   Recent studies have shown an increased risk of liver cancer among HCV 
infected people ranging from 23 to 35-fold.4   Other studies have shown associations between HBV or HCV 
infection and non-Hodgkin lymphoma (NHL) and lung cancer.4,5   
Hepatitis B vaccination can prevent HBV infection.  While there is currently no hepatitis C vaccine, 
effective anti-viral treatments exist to prevent progression to cirrhosis, the stage of liver disease where the 
majority of liver cancers develop.6   
Our objective was to explore the association of HBV and HCV with liver cancer and examine trends in liver 
cancer from 2002 to 2012 as well as assess associations with other cancers. 
METHODS 
HBV and HCV surveillance data are collected using a web-based system, the MA Virtual Epidemiologic 
Network (MAVEN).  MAVEN is maintained by the Bureau of Infectious Disease and Laboratory Sciences 
(BIDLS) within the Massachusetts Department of Public Health.  Demographics, clinical characteristics, 
risk history, and viral hepatitis laboratory results are collected when available.  The Massachusetts Cancer 
Registry (MCR) collects information on all newly diagnosed cases of in situ and invasive cancers and 
benign brain tumors among Massachusetts residents from hospitals, nursing homes, doctors’ offices, 
radiation centers and 43 state and territory central cancer registries. For the sake of brevity in this report, the 
term ‘cancer’ in reference to MCR cases will include invasive and in situ cancers and benign brain tumors. 
HBV and HCV and MCR data were matched on name and date of birth using Link Plus TM software, a 
probabilistic record linkage program developed at CDC’s Division of Cancer Prevention and Control in 
support of CDC’s National Program of Cancer Registries (NPCR).7 Percentages of individual cancers 
among HBV- or HCV-infected MCR cases were compared with percentages among all MCR cases.  The 
population proportions were compared using a T-test to determine statistical significance at the p<.05 level.  
Using cumulative age-adjusted incidence rates, relative risks were calculated for being diagnosed with all 
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cancers, liver cancer, and a non-liver cancer among people in the MCR with and without HBV or HCV 
infections.  The annual percent change (APC) was calculated for incidence trends in liver cancer using 
Joinpoint software from the National Cancer Institute.8     
RESULTS 
Between 2002 and 2012, there were 28,070 HBV and 94,701 HCV chronic and acute infections reported to 
the MDPH.  During the same time period, there were 447,087 cancer cases reported to the MCR.   Of the 
HBV cases, 5.2% (n=1,471) matched with an MCR case while 5.8% of HCV cases matched with an MCR 
case (n=5,499).  Of the MCR cancer cases, 1.5% (n=6,970) had an HBV or HCV infection reported from 
2002 to 2012. 
Liver cancer was the most common cancer among males and third most common among females infected 
with HBV or HCV (Table 1).   
Table 1. MCR Cases with Hepatitis B or C infection (2002-2012)* 
Males: HBV/HCV 
Cancers 
All Cancers % Infected with 
HBV/HCV 
1) Liver 1,349 (28.6%) 4,285 (2.0%) 31.5% 
2) Prostate 576 (12.2%) 55,105 (26.1%) 1.0% 
3) Lung 500 (10.6%) 27,295 (12.9%) 1.8% 
4) Others 2,287 (48.5%) 125,720 (59.2%) 1.8% 
              TOTAL  4,712 (100%) 212,405 (100%) 2.2% 
 
Females: HBV/HCV 
Cancers 
All Cancers % Infected with 
HBV/HCV 
1) Breast 433 (19.2%) 57,762 (24.6%) 0.7% 
2) Lung 268 (11.9%) 28,172 (12.0%) 1.0% 
3) Liver 238 (10.6%) 1,484 (0.6%) 16.1% 
4) Others 1,315 (58.3%) 147,239 (62.7%) 0.9% 
              TOTAL 2,254 (100%) 234,657 (100%) 1.0% 
              *-Note that there were 4 transgender HBV/HCV cases and 25 for all cancers. 
Liver cancer was disproportionately represented among HBV/HCV cancers for both males and females; 
28.6% and 10.6% of liver cancers among males and females, respectively, were infected with HBV or 
HCV.  Additionally non-Hodgkin lymphoma (NHL) was also disproportionately represented among 
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HBV/HCV cancers for both males (6.1% vs. 4.2%) and females (6.6% vs. 3.7%) (data not shown).   These 
proportional differences were all statistically significant (p<.05).  The other specific cancers in Table 1 
(prostate, breast, and lung), while representing the top 3 percentages of HBV/HCV cancers, were not 
overrepresented among HBV and HCV cancer cases compared to their representation among all cancer 
cases. 
Among males, a significantly higher percentage of HBV/HCV cancers among Asian, non-Hispanics (NHs) 
included liver (46.7%) compared to 27.1% of white, NHs, 24.7% of black, NHs, and 36.7% of Hispanics.  
Also seen among Asian, NHs females, was a significantly higher percentage of HBV/HCV-related  liver 
cancer (23.4%) compared to 9.3% of white, NHs, 12.2% of black, NHs, and 14.8% of Hispanic females.   
Between 2002 and 2012, people with HCV infection had 13 times the risk of liver cancer than did people 
without HCV infection and people with HBV infection had 15 times the risk of liver cancer than did people 
without HBV infection. 
Table 2. Hepatitis B and C Infection and Cancer Relative Risks, 2002-2012 
Hepatitis C and Cancer (n=5,499) 
 Relative Risk 95% Confidence Interval 
All Cancers 0.6 0.6, 0.6 
Liver Cancer 13.1 12.2, 13.9 
Non Liver Cancer 0.5 0.5, 0.5 
 
Hepatitis B and Cancer (n=1,471) 
 Relative Risk Confidence Interval 
All Cancers 0.7 0.6, 0.7 
Liver Cancer 15.3 13.7, 17.1 
Non Liver Cancer 0.5 0.5, 0.6 
 
The incidence rates for liver cancer for both males and females in Massachusetts increased significantly 
from 2002-2012 (APC=3.9 and APC=3.6, respectively).  In addition, there were significant increases in 
trends for white, NHs (APC=6.5) and black, NHs (APC=3.3).  Among MCR cases, 31.5% of males with 
liver cancer and 16.1% of females with liver cancer were infected with HBV or HCV.   
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LIMITATIONS 
Prior to the electronic reporting with MAVEN in 2006, manual laboratory reporting was used and thus 
earlier years may be incomplete, resulting in fewer records available for the match and the potential for an 
underestimation of the association with cancer. HBV and HCV diagnosis date reflects the date of symptom 
onset, specimen collection date for the first lab result or MDPH notification date, whichever is the earliest, 
resulting  in a possible misclassification of year of hepatitis infection. Likewise, MCR diagnosis date 
reflects the date the tumor was first diagnosed and not when the tumor first became malignant. 
CONCLUSIONS 
Liver cancer was statistically associated with prior HBV or HCV infection among Massachusetts residents 
from 2002 to 2012.  The trends in liver cancer from 2002 to 2012 revealed a significant increase among 
males and females and white and black, non-Hispanics.  These trends are certainly driven in part by HBV 
and HCV infections.  It is estimated that 50% of liver cancers in the U.S. are HCV related, 15% are HBV 
related, and 35% are related to something else.(ref)  Eighty-one percent of Americans with chronic HCV 
infection were born between 1945 and 1965.  Many of those people were infected before the discovery of 
HCV in 1989 and have been living with an infection for at least twenty years, resulting in more liver cancer 
occurring as this population ages and enters the final stages of HCV infection. 9 The strong association 
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between HBC and HCV infection and liver cancer underscores the importance of prevention of liver cancer 
through hepatitis B vaccination and prompt antiviral treatment for HBV and HCV infected people. 
 Among MCR cases infected with HBV or HCV, non-Hodgkin lymphoma (NHL) was disproportionately 
represented among males and females. While this association was statistically significant, the 
disproportions were not as large as for liver cancer.  HBV and HCV have strong lymphotropic properties 
(stimulating or acting on lymphatic system) and data have shown a causal association with NHL.4 This 
association with NHL, while not as strong as the association with liver cancer, has some biological 
foundation and further supports vaccination and early treatment for people with HBV and HCV infections. 
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Figure 1. 
PERCENTAGE OF CANCER INCIDENT CASES BY CANCER TYPE AND SEX 
Massachusetts, 2010-2014  
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Figure 2. 
INCIDENCE RATES1 FOR TEN LEADING CANCER TYPES BY SEX 
Massachusetts, 2010-2014  
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1Rates are age-adjusted to the 2000 U.S. Standard Population.  NOS – Not Otherwise Specified. 
 Source:  Massachusetts Cancer Registry 
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Figure 3. 
PERCENTAGE OF CANCER DEATHS BY CANCER TYPE AND SEX 
Massachusetts, 2010-2014 
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Figure 4. 
MORTALITY RATES1 FOR TEN LEADING CANCER TYPES BY SEX 
Massachusetts, 2010-2014 
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1Rates are age-adjusted to the 2000 U.S. Standard Population.  *NOS – Not Otherwise Specified. 
 Source:  Massachusetts Vital Statistics 
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Table 1.  
AGE-SPECIFIC INCIDENCE RATES1 AND MEDIAN AGE AT DIAGNOSIS FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
MALES 
 
 
 
 
_______________________________________________________________________________ 
1 per 100,000    2 Breast in situ is excluded from ‘All Sites’.  3 Dashes indicate age groups with no incident cases.  Source: Massachusetts Cancer Registry
Cancer Site / Type 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ 
Median 
Age 
All Sites 28.2 12.3 13.2 23.0 38.1 54.1 74.8 100.8 164.7 290.3 569.5 928.7 1375.6 1918.7 2478.4 2704.8 2838.6 2845.0 66 
Brain & Other Nervous 
System 5.8 4.1 2.9 2.9 2.7 5.0 3.9 3.5 4.9 6.8 8.5 11.8 15.9 20.7 25.6 31.2 29.4 23.2 59 
Breast -- 0.1 -- -- -- -- 0.3 0.2 0.6 0.7 1.7 2.1 3.1 5.7 7.4 8.0 10.2 7.9 68 
Breast in situ2     -- -- -- 0.1 -- 0.1 0.2 0.1 0.5 0.3 0.1 0.8 0.9 0.4 0.4 62 
Bronchus & Lung -- -- 0.1 0.2 0.6 0.3 1.5 3.0 8.4 20.1 52.0 104.5 163.0 269.6 417.9 524.2 554.2 451.9 71 
Colon / Rectum -- -- 0.1 0.3 0.8 2.0 5.6 10.1 20.7 32.4 69.0 66.8 89.6 129.9 184.1 225.0 269.4 341.4 67 
Esophagus -- -- -- -- 0.1 0.2 0.3 0.6 1.8 6.3 10.3 19.4 31.5 39.2 55.2 53.3 58.4 53.0 67 
Hodgkin Lymphoma -- 0.4 1.2 2.6 5.7 5.9 4.9 3.5 4.1 3.5 3.2 2.7 3.9 4.3 5.3 4.9 4.9 4.6 41 
Kidney & Renal Pelvis 2.6 0.6 -- 0.2 0.6 1.7 3.6 8.3 14.2 22.2 32.8 43.5 63.3 79.8 93.9 95.2 88.2 68.7 63 
Larynx -- -- 0.1 -- -- 0.2 0.2 0.4 0.7 3.2 7.0 14.2 17.9 23.5 30.3 30.1 36.2 17.8 66 
Leukemia 8.8 3 3.2 3.6 3.5 3.0 4.0 4.1 6.8 10.3 12.3 20.7 34.0 48.5 67.7 90.3 102.8 115.9 67 
Liver & Intrahepatic Bile 
Ducts 1.4 -- 0.3 0.2 0.5 0.2 0.5 1.3 2.5 7.3 20.3 40.5 50.1 43.4 53.1 62.8 62.2 44.7 63 
Melanoma of Skin -- -- 0.2 0.4 1.5 3.8 8.2 8.0 13.9 18.9 27.5 45.5 56.7 78.8 110.9 142.7 160.5 149.0 66 
Multiple Myeloma -- -- -- -- -- 0.3 0.1 1.6 2.4 6.5 8.6 13.5 20.4 27.3 43.8 40.7 61.0 46.3 67 
Non-Hodgkin Lymphoma 1.1 1.1 0.4 2.2 3.2 3.0 5.8 8.3 12.6 17.7 25.4 35.3 47.9 75.9 98.0 115.2 146.9 144.8 66 
Oral Cavity & Pharynx 0.1 0.1 0.1 0.5 0.6 1.7 2.3 4.1 9.1 20.6 33.0 47.5 62.5 64.5 67.1 73.7 53.9 52.6 62 
Pancreas -- -- 0.1  0.1 0.3 0.7 1.7 3.2 7.3 13.2 25.3 33.4 54.1 65.8 86.0 98.7 107.2 69 
Prostate 0.1 -- -- -- -- -- 0.1 0.4 9.7 40.4 151.8 292.5 477.3 646.5 670.3 515.3 329.6 331.9 65 
Stomach -- -- 0.1 -- -- 0.3 1.2 2.0 2.8 5.0 10.1 15.5 20.6 32.2 46.6 58.5 72.3 73.2 69 
Testis 0.7 0.3 0.1 3.1 10.3 15.6 14.4 13.4 10.8 8.3 6.6 3.8 2.1 1.4 1.7 0.6 0.8 0.8 35 
Thyroid 0.3 -- 0.6 1.0 2.7 5.2 8.2 11.7 13.9 17.1 17.3 22.2 22.2 23.8 26.7 22.4 18.1 8.3 54.5 
Urinary Bladder -- -- -- 0.2 0.7 0.8 1.4 2.2 6.6 11.2 26.1 45.0 80.3 137.5 226.4 280.0 344.7 403.5 72 
Other Sites 7.4 2.6 3.7 5.6 4.5 4.7 7.6 12.0 15.0 24.6 32.6 56.3 79.8 112.0 180.7 244.8 336.4 398.5 70 
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Table 2.  
AGE-SPECIFIC INCIDENCE RATES1 AND MEDIAN AGE AT DIAGNOSIS FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
FEMALES 
 
 
 
 
 
 
_____________________________________________________________________________ 
1 per 100,000    2 Breast in situ is excluded from ‘All Sites’.  3 Dashes indicate age groups with no incident cases. Source: Massachusetts Cancer Registry
Cancer Site / Type 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ 
Median 
Age 
All Sites 23.6 12.1 16.1 20.9 45.6 72.8 127.2 196.2 331.4 472.8 661.9 814.4 1098.0 1448.3 1810.7 2039.0 2085.6 1828.2 65 
Brain & Other Nervous System 4.0 3.6 3.8 2.8 2.4 2.1 2.7 3.3 4.7 4.3 5.8 9.1 11.6 14.5 16.3 20.5 17.3 17.7 60 
Breast -- -- 0.1 -- 1.9 10.1 29.0 67.3 141.2 213.2 251.2 271.9 366.1 452.9 502.7 493.3 451.9 327.8 62 
Breast in situ2 -- -- -- 0.3 0.2 1.2 4.5 15.4 68.6 104.4 103.4 94.5 105.5 126.0 118.8 105.1 66.6 27.7 57 
Bronchus & Lung 0.1 -- 0.1 0.4 0.5 0.2 0.8 3.2 11.2 26.3 60.6 93.8 147.6 247.1 375.6 438.0 399.6 262.2 71 
Cervix Uteri -- -- -- 0.1 0.5 3.1 6.9 9.3 10.5 8.7 8.2 7.9 9.1 9.8 6.8 8.4 7.8 6.2 51 
Colon / Rectum -- 0.1 0.3 0.3 1.2 2.1 4.4 11.1 20.1 27.8 52.7 47.4 61.9 91.5 130.4 186.3 235.0 265.1 72 
Corpus Uteri & Uterus, NOS -- -- 0.1 -- 0.1 1.4 3.1 9.0 14.1 27.6 54.5 83.7 111.8 126.8 117.0 96.3 82.0 56.6 63 
Esophagus -- -- -- -- -- -- 0.3 0.6 0.6 0.9 1.2 4.0 5.9 9.6 14.8 12.1 14.4 13.5 71 
Hodgkin Lymphoma -- 0.1 1.0 3.3 6.1 3.9 3.8 2.8 2.8 1.3 2.2 2.7 2.3 2.5 3.3 3.9 5.6 1.7 38 
Kidney & Renal Pelvis 1.7 0.7 0.2 0.3 0.4 0.9 2.3 4.1 7.5 10.0 16.6 19.6 28.2 34.4 47.4 54.0 45.9 34.1 65 
Larynx -- -- -- -- -- -- 0.1 0.1 0.3 0.9 2.8 4.0 2.8 7.1 8.3 5.6 6.3 5.2 67 
Leukemia 7.9 4.2 2.1 1.6 3.0 3.1 3.0 3.2 5.8 5.8 8.9 13.7 19.5 23.9 35.4 50.4 52.9 60.0 68 
Liver & Intrahepatic Bile Ducts 0.3 -- 0.2 0.2 0.3 0.5 0.5 0.9 1.7 3.9 9.0 12.4 12.7 15.8 22.0 23.2 18.5 . 68 
Melanoma of Skin -- -- 0.3 1.1 4.9 10.5 13.4 11.1 16.9 21.1 27.4 32.2 38.9 42.8 51.2 55.1 61.7 61.0 61 
Multiple Myeloma -- -- -- -- -- 0.3 0.4 0.9 1.3 3.2 6.6 9.0 13.2 20.3 23.8 29.9 34.2 31.4 70 
Non-Hodgkin Lymphoma 0.1 0.7 0.9 1.1 1.7 2.7 4.1 5.5 8.3 12.1 19.9 28.1 41.9 53.7 68.9 81.4 103.2 88.3 68 
Oral Cavity & Pharynx 0.1 0.1 0.4 0.5 0.6 0.6 1.5 2.7 3.7 5.5 10.8 15.1 18.0 24.6 27.4 29.7 32.9 33.5 66 
Ovary 0.2 0.1 0.4 0.9 1.6 2.3 3.5 4.2 7.0 13.6 21.1 25.7 30.3 37.7 43.8 43.5 43.7 38.5 63 
Pancreas -- -- -- -- 0.1 0.1 0.4 1.3 2.6 4.3 8.8 15.2 25.7 42.6 60.1 71.1 84.2 100.6 74 
Stomach -- -- -- 0.3 0.3 0.3 0.5 1.1 3.6 4.0 4.7 7.3 8.2 11.8 18.8 23.5 34.9 37.7 72 
Thyroid 0.2 0.1 1.8 4.3 17.1 24.6 39.1 44.2 49.1 53.2 52.6 46.8 44.9 47.6 39.9 34.9 24.4 13.5 49 
Urinary Bladder -- -- 0.1 0.2 0.2 0.1 0.6 1.0 2.3 3.7 8.2 16.2 26.3 39.6 61.3 80.3 88.3 82.9 73 
Other Sites 8.8 2.2 4.2 3.5 2.8 4.4 7.1 10.5 17.0 23.7 33.4 52.0 71.3 94.6 141.5 199.0 236.2 272.4 72 
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Table 3.  
AGE-SPECIFIC INCIDENCE RATES1 AND MEDIAN AGE AT DIAGNOSIS FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
TOTAL 
 
 
 
_____________________________________________________________________________ 
1 per 100,000    2 Breast in situ is excluded from ‘All Sites’.  3 Dashes indicate age groups with no incident cases or cancers found in only one sex. Source: Massachusetts 
Cancer Registry
Cancer Site / Type 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ 
Median 
Age 
All Sites 26.0 12.2 14.6 22.0 41.9 63.5 101.4 149.5 250.2 383.8 616.9 869.6 1230.3 1668.3 2111.7 2324.7 2381.7 2151.0 66 
Brain & Other Nervous System 4.9 3.9 3.3 2.9 2.6 3.5 3.3 3.4 4.8 5.5 7.1 10.4 13.6 17.4 20.5 25.1 22.1 19.4 59 
Breast -- 0.1 0.0 -- 1.0 5.1 14.8 34.4 72.7 109.5 129.7 141.8 193.3 243.9 279.5 285.1 278.2 226.3 62 
Breast in situ2 -- -- -- 0.1 0.1 0.6 2.3 7.9 35.2 53.5 53.1 49.2 55.4 67.2 65.6 60.4 40.6 19.0 57 
Bronchus & Lung 0.1 -- 0.1 0.3 0.5 0.3 1.2 3.1 9.8 23.3 56.4 98.9 155.0 257.6 394.7 475.0 460.4 322.4 71 
Cervix Uteri -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Colon / Rectum -- 0.1 0.2 0.3 1.0 2.0 5.0 10.6 20.4 30.0 60.7 56.7 75.1 109.5 154.6 202.9 248.5 289.3 69 
Corpus Uteri & Uterus, NOS -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Esophagus -- -- -- -- 0.0 0.1 0.3 0.3 1.2 3.5 5.6 11.4 18.0 23.4 33.0 29.8 31.7 26.0 68 
Hodgkin Lymphoma -- 0.3 1.1 3.0 5.9 4.9 4.4 3.2 3.4 2.4 2.6 2.7 3.1 3.4 4.2 4.3 5.3 2.6 40 
Kidney & Renal Pelvis 2.1 0.7 0.1 0.2 0.5 1.3 3.0 6.1 10.8 16.0 24.5 31.1 44.9 55.6 68.4 71.7 62.5 45.0 64 
Larynx -- -- 0.0 -- -- 0.1 0.1 0.2 0.5 2.0 4.8 8.9 10.0 14.8 18.2 16.1 18.1 9.2 66 
Leukemia 8.4 3.6 2.7 2.6 3.2 3.1 3.5 3.7 6.3 8.0 10.6 17.0 26.4 35.4 50.0 67.5 72.6 77.7 67 
Liver & Intrahepatic Bile Ducts 0.9 -- 0.2 0.2 0.4 0.1 0.5 0.9 1.7 4.4 11.9 24.3 30.4 27.0 32.6 39.5 38.5 26.8 64 
Melanoma of Skin -- -- 0.2 0.8 3.2 7.2 10.8 9.6 15.4 20.0 27.5 38.6 47.4 59.7 78.1 92.7 100.7 88.9 64 
Multiple Myeloma -- -- -- -- -- 0.3 0.2 1.2 1.8 4.8 7.6 11.2 16.6 23.6 32.8 34.6 44.7 36.1 69 
Non-Hodgkin Lymphoma 0.6 0.9 0.6 1.7 2.5 2.8 4.9 6.9 10.4 14.9 22.6 31.6 44.8 64.1 82.0 95.9 120.4 106.2 67 
Oral Cavity & Pharynx 0.1 0.1 0.2 0.5 0.6 1.2 1.9 3.4 6.3 12.9 21.6 30.7 39.2 43.2 45.3 48.6 41.2 39.5 63 
Ovary -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Pancreas -- -- 0.0 -- 0.1 0.2 0.5 1.5 2.9 5.8 10.9 20.1 29.3 48.0 62.7 77.5 89.9 102.7 71 
Prostate -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Stomach -- -- 0.0 0.1 0.2 0.3 0.8 1.5 3.2 4.5 7.3 11.2 14.1 21.3 31.3 38.5 49.6 49.0 70 
Testis -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Thyroid 0.3 0.1 1.2 2.7 9.9 15.0 23.9 28.3 31.9 35.6 35.4 35.0 34.1 36.5 34.0 29.5 21.9 11.8 51 
Urinary Bladder -- -- 0.0 0.2 0.4 0.4 1.0 1.6 4.4 7.4 16.9 30.1 52.1 85.4 135.7 166.0 189.1 184.6 72 
Other Sites 8.1 2.4 3.9 4.6 3.7 4.5 7.4 11.2 16.1 24.1 33.0 54.1 75.4 102.7 159.2 218.6 275.6 312.6 71 
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Figure 5. 
ANNUAL PERCENT CHANGE (APC) IN AGE-ADJUSTED CANCER RATES AMONG MALES 
Massachusetts, 2010-2014  
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 *APC is statistically significant (p < 0.05).  Values appearing directly on a bar have been bolded for ease of reading only.  Source: Massachusetts Cancer Registry.                                          
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Figure 6. 
ANNUAL PERCENT CHANGE (APC) IN AGE-ADJUSTED CANCER RATES AMONG FEMALES 
Massachusetts, 2010-2014 
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*APC is statistically significant (p < 0.05).  Values appearing directly on a bar have been bolded for ease of reading only. Source: Massachusetts Cancer Registry.                                         
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Table 4. 
ANNUAL AGE-ADJUSTED1 INCIDENCE RATES2 FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
MALES 
Cancer Site / Type 2010 2011 2012 2013 2014 
All Sites 532.9 538.8 500.2 482.9 479.4 
Brain & Other Nervous System 8.3 7.9 7.4 9.1 7.5 
Breast 1.2 1.5 1.2 1.5 1.7 
Breast in situ3  0.2 0.2 0.2 0.1 0.1 
Bronchus & Lung 73.3 74.6 71.3 67.0 68.1 
Colon / Rectum 44.7 43.5 42.2 40.7 44.0 
Esophagus 9.9 11.0 9.8 9.8 9.1 
Hodgkin Lymphoma 3.4 3.6 3.6 3.1 3.2 
Kidney & Renal Pelvis 20.0 20.6 20.8 23.3 23.2 
Larynx 6.0 5.3 5.2 6.3 5.7 
Leukemia 15.8 17.4 17.6 16.1 16.3 
Liver & Intrahepatic Bile Ducts 12.9 12.4 14.2 12.5 12.4 
Melanoma of Skin 25.0 29.1 25.8 25.0 22.8 
Multiple Myeloma 7.8 7.9 8.2 8.8 7.5 
Non-Hodgkin Lymphoma 23.7 22.1 22.6 23.2 23.4 
Oral Cavity & Pharynx 17.7 18.0 18.7 16.8 18.0 
Pancreas 13.0 14.3 14.3 14.7 13.9 
Prostate 140.5 138.2 106.9 97.6 92.9 
Stomach 10.0 9.0 8.9 10.3 9.9 
Testis 5.6 6.7 6.7 6.6 6.5 
Thyroid 9.4 10.8 10.4 9.3 11.6 
Urinary Bladder 40.3 41.6 42.3 39.6 39.0 
 
 
 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2per 100,000 males 
3Breast in situ is excluded from “All Sites” 
 
Source: Massachusetts Cancer Registry 
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Table 5. 
ANNUAL AGE-ADJUSTED1 INCIDENCE RATES2 FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
FEMALES 
Cancer Site / Type 2010 2011 2012 2013 2014 
All Sites 444.4 457.4 457.0 447.0 446.5 
Brain & Other Nervous System 5.8 6.3 5.6 6.1 5.6 
Breast 130.7 137.3 137.1 137.4 138.6 
Breast in situ3  44.9 41.6 42.6 42.6 40.9 
Bronchus & Lung 62.7 60.7 61.2 60.7 58.5 
Cervix Uteri 5.6 5.1 5.0 4.9 5.5 
Colon / Rectum  35.9 34.3 33.2 33.1 32.3 
Corpus Uteri & Uterus, NOS 28.1 31.2 28.3 29.8 27.6 
Esophagus 2.4 2.0 1.7 2.4 2.6 
Hodgkin Lymphoma 2.6 2.7 2.6 2.4 2.7 
Kidney & Renal Pelvis 10.4 10.6 10.9 10.7 10.8 
Larynx 1.5 1.4 1.8 1.2 1.2 
Leukemia 10.7 10.3 10.0 10.2 9.1 
Liver & Intrahepatic Bile Ducts 3.5 3.3 3.8 4.1 4.0 
Melanoma of Skin 18.4 18.6 17.8 16.2 15.6 
Multiple Myeloma 4.4 6.0 5.2 5.3 4.9 
Non-Hodgkin Lymphoma 16.7 15.5 17.8 16.7 15.8 
Oral Cavity & Pharynx 6.5 6.2 7.9 7.3 6.7 
Ovary 10.6 12.2 12.9 10.5 11.3 
Pancreas 10.7 11.0 11.0 11.6 12.1 
Stomach 4.7 4.5 4.3 4.4 5.0 
Thyroid 27.4 30.7 29.7 26.9 31.2 
Urinary Bladder 10.9 12.1 11.7 10.8 10.9 
 
 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2per 100,000 males 
3Breast in situ is excluded from “All Sites” 
 
Source: Massachusetts Cancer Registry 
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Table 6. 
ANNUAL AGE-ADJUSTED1 INCIDENCE RATES2 FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
TOTAL 
Cancer Site / Type 2010 2011 2012 2013 2014 
All Sites 479.5 489.8 472.4 459.3 456.9 
Brain & Other Nervous System 7.0 7.0 6.4 7.5 6.4 
Breast -- -- -- -- -- 
Breast in situ3  -- -- -- -- -- 
Bronchus & Lung 66.7 66.4 65.1 63.1 62.3 
Cervix Uteri -- -- -- -- -- 
Colon / Rectum 39.8 38.3 37.2 36.5 37.5 
Corpus Uteri & Uterus, NOS -- -- -- -- -- 
Esophagus 5.7 5.9 5.3 5.7 5.5 
Hodgkin Lymphoma 3.0 3.1 3.1 2.7 3.0 
Kidney & Renal Pelvis 14.8 15.2 15.5 16.4 16.5 
Larynx 3.5 3.2 3.3 3.5 3.2 
Leukemia 12.8 13.4 13.4 12.8 12.2 
Liver & Intrahepatic Bile Ducts 7.8 7.5 8.5 8.0 7.8 
Melanoma of Skin 21.1 22.9 21.0 19.8 18.7 
Multiple Myeloma 5.9 6.9 6.5 6.8 6.1 
Non-Hodgkin Lymphoma 19.8 18.3 19.8 19.6 19.2 
Oral Cavity & Pharynx 11.7 11.6 12.9 11.7 11.9 
Ovary -- -- -- -- -- 
Pancreas 11.8 12.5 12.6 13.0 12.9 
Prostate -- -- -- -- -- 
Stomach 6.9 6.5 6.4 7.0 7.2 
Testis -- -- -- -- -- 
Thyroid 18.7 21.0 20.3 18.4 21.7 
Urinary Bladder 23.2 24.6 24.8 23.1 22.8 
 
 
 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2per 100,000 total population 
3Breast in situ is excluded from “All Sites” 
4Dashes indicate cancers found in only one sex or predominantly in one sex (breast cancer). 
 
Source: Massachusetts Cancer Registry
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Table 7. 
ANNUAL AGE-ADJUSTED1 MORTALITY RATES2 FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
MALES 
 
 
 
Cancer Site / Type 2010 2011 2012 2013 2014 
All Sites 199.8 194.2 187.2 186.0 184.6 
Brain & Other Nervous System 4.9 5.1 4.9 5.2 5.1 
Breast 0.2 0.2 0.4 0.4 0.4 
Bronchus & Lung 49.9 47.9 48.6 47.3 46.8 
Colon / Rectum 15.4 14.8 14.6 14.1 15.0 
Esophagus 7.5 8.3 8.5 7.6 8.2 
Hodgkin Lymphoma 0.5 0.2 0.3 0.3 0.3 
Kidney & Renal Pelvis 3.6 4.0 4.5 4.8 5.4 
Larynx 1.7 1.6 1.2 1.4 1.5 
Leukemia 8.2 8.4 8.1 9.1 8.2 
Liver & Intrahepatic Bile Ducts 9.0 9.0 8.8 10.5 9.7 
Melanoma of Skin 4.0 3.7 3.8 4.1 3.9 
Multiple Myeloma 3.3 3.8 3.7 3.4 4.2 
Non-Hodgkin Lymphoma 6.7 7.1 5.9 6.4 6.6 
Oral Cavity & Pharynx 3.9 3.5 3.6 3.6 3.2 
Pancreas 10.8 11.9 11.2 12.6 12.0 
Prostate 18.4 17.3 17.5 17.8 18.2 
Stomach 3.8 3.8 3.9 3.5 4.2 
Testis 0.1 0.1 0.2 0.2 0.03 
Thyroid 0.4 0.7 0.6 0.8 0.5 
Urinary Bladder 8.4 7.5 7.2 7.9 7.7 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 males 
 
Source: Massachusetts Vital Statistics 
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Table 8 
ANNUAL AGE-ADJUSTED1 MORTALITY RATES2 FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
FEMALES 
 
 
 
Cancer Site / Type 2010 2011 2012 2013 2014 
All Sites 140.1 137.1 136.2 136.2 130.1 
Brain & Other Nervous System 3.1 3.3 3.5 3.3 3.1 
Breast 17.0 17.9 18.1 17.8 18.1 
Bronchus & Lung 36.6 35.7 36.0 35.1 35.1 
Cervix Uteri 1.2 1.4 1.1 0.9 1.3 
Colon / Rectum 11.7 9.9 10.5 11.1 10.2 
Corpus Uteri & Uterus, NOS 3.9 4.3 3.9 4.9 4.4 
Esophagus 1.7 1.5 1.4 1.3 1.9 
Hodgkin Lymphoma 0.3 0.3 0.2 0.2 0.1 
Kidney & Renal Pelvis 1.7 2.2 1.9 2.1 1.8 
Larynx 0.5 0.5 0.3 0.4 0.3 
Leukemia 4.6 4.5 4.7 5.1 4.4 
Liver & Intrahepatic Bile Ducts 3.4 2.9 3.2 3.7 3.7 
Melanoma of Skin 1.6 1.8 1.8 2.1 1.8 
Multiple Myeloma 2.3 2.5 2.7 2.6 2.6 
Non-Hodgkin Lymphoma 4.2 4.0 4.1 4.3 4.1 
Oral Cavity & Pharynx 1.7 1.1 1.1 1.2 1.3 
Ovary 6.4 7.7 6.7 7.8 6.6 
Pancreas 9.2 9.4 9.2 9.0 9.7 
Stomach 2.3 2.1 2.2 2.5 2.2 
Thyroid 0.6 0.5 0.2 0.5 0.4 
Urinary Bladder 2.5 2.3 2.4 2.7 2.1 
 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 females 
 
Source: Massachusetts Vital Statistics 
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Table 9. 
ANNUAL AGE-ADJUSTED1 MORTALITY RATES2 FOR SELECTED CANCER SITES 
Massachusetts, 2010-2014 
TOTAL3 
 
 
 
Cancer Site / Type 2010 2011 2012 2013 2014 
All Sites 163.8 160.0 157.0 156.3 152.4 
Brain & Other Nervous System 3.7 4.2 4.1 4.1 4.2 
Breast - - - - - 
Bronchus & Lung 42.1 40.8 41.3 40.1 39.9 
Cervix Uteri - - - - - 
Colon / Rectum 13.3 12.0 12.2 12.4 12.3 
Corpus Uteri & Uterus, NOS - - - - - 
Esophagus 4.3 4.4 4.5 4.0 4.7 
Hodgkin Lymphoma 0.4 0.2 0.2 0.3 0.2 
Kidney & Renal Pelvis 2.5 3.0 3.1 3.2 3.4 
Larynx 1.0 1.0 0.7 0.8 0.8 
Leukemia 6.1 6.2 6.2 6.8 5.9 
Liver & Intrahepatic Bile Ducts 5.9 5.7 5.7 6.8 6.3 
Melanoma of Skin 2.6 2.6 2.6 2.9 2.6 
Multiple Myeloma 2.7 3.1 3.2 2.9 3.3 
Non-Hodgkin Lymphoma 5.3 5.3 4.8 5.2 5.2 
Oral Cavity & Pharynx 2.7 2.2 2.2 2.3 2.2 
Ovary 3.6 4.3 3.8 4.4 3.7 
Pancreas 9.9 10.5 10.2 10.6 10.7 
Prostate - - - - - 
Stomach 2.9 2.8 3.0 2.9 3.1 
Testis - - - - - 
Thyroid 0.5 0.6 0.4 0.6 0.4 
Urinary Bladder 4.9 4.4 4.3 4.7 4.4 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 total population 
3Dashes indicate cancers found in only one sex or predominantly in one sex (breast cancer). 
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Table 10. 
FIVE LEADING CANCER INCIDENCE RATES BY RACE/ETHNICITY AND SEX 
 Massachusetts, 2010-2014   
   
MALES 
 
AGE-ADJUSTED1 INCIDENCE RATE2 
RANK White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
1 
Prostate 
106.3 
 
Prostate 
198.5 
 
Bronchus & Lung 
58.5 
 
Prostate 
123.1 
 
2 
Bronchus & Lung 
72.5 
 
Bronchus & Lung 
69.7 
 
Prostate 
56.7 
Bronchus & Lung 
39.7 
 
3 
Colon / Rectum 
43.0 
 
Colon / Rectum 
46.8 
 
Colon / Rectum 
34.5 
 
Colon / Rectum 
36.2 
 
4 
Urinary Bladder 
42.9 
 
Kidney & Renal Pelvis 
21.1 
 
Liver & Intrahepatic 
Bile Ducts 
28.5 
 
Liver & 
Intrahepatic Bile 
Ducts 
23.0 
5 
Melanoma of Skin 
27.8 
 
Liver & Intrahepatic 
Bile Ducts 
20.0 
 
Urinary Bladder 
14.4 
 
Non-Hodgkin 
Lymphoma 
19.5 
 
 
FEMALES 
 
AGE-ADJUSTED1 INCIDENCE RATE2 
RANK White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
1 
Breast3 
142.3 
 
Breast 
116.4 
 
Breast 
90.2 
 
Breast 
88.4 
 
2 
Bronchus & Lung 
64.1 
 
Bronchus & Lung 
46.8 
 
Bronchus & Lung 
33.7 
 
Bronchus & Lung 
28.4 
 
3 
Colon / Rectum 
33.7 
 
Colon / Rectum 
37.2 
 
Colon / Rectum 
28.5 
 
Thyroid 
27.5 
 
4 
Corpus Uteri & 
Uterus, NOS 
30.2 
 
Corpus Uteri & 
Uterus, NOS 
24.8 
 
Thyroid 
27.7 
 
Colon / Rectum 
27.2 
5 
Thyroid 
29.5 
 
Thyroid 
23.4 
Corpus Uteri & 
Uterus, NOS 
13.2 
 
Corpus Uteri & 
Uterus, NOS 
21.2 
 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 
3Breast cancer rates do not include in situ cases.  
 
Source:  Massachusetts Cancer Registry 
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Table 11.  
NUMBER AND PERCENTAGE OF INCIDENT CASES FOR SELECTED CANCER SITES BY RACE/ETHNICITY1 
Massachusetts, 2010-2014 
MALES 
 
  All Races2 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Cancer Site / Type Cases % of Cases Cases % of Cases Cases % of Cases Cases % of Cases Cases % of Cases 
All Sites 87975 100.0 76150 100.0 4498 100.0 2109 100.0 3270 100.0 
Brain & Other Nervous System 1351 1.5 1193 1.6 47 1.0 27 1.3 71 2.2 
Breast3 244 0.3 216 0.3 9 0.2 12 0.6 6 0.2 
Bronchus & Lung 11951 13.6 10783 14.2 512 11.4 341 16.2 267 8.2 
Colon / Rectum 7338 8.3 6361 8.4 381 8.5 235 11.1 267 8.2 
Esophagus 1745 2.0 1612 2.1 58 1.3 36 1.7 26 0.8 
Hodgkin Lymphoma 558 0.6 447 0.6 38 0.8 16 0.8 50 1.5 
Kidney & Renal Pelvis 3809 4.3 3340 4.4 182 4.0 72 3.4 167 5.1 
Larynx 1017 1.2 894 1.2 47 1.0 11 0.5 50 1.5 
Leukemia 2769 3.1 2418 3.2 107 2.4 59 2.8 110 3.4 
Liver & Intrahepatic Bile Ducts 2368 2.7 1757 2.3 188 4.2 199 9.4 199 6.1 
Melanoma of Skin 4342 4.9 4064 5.3 8 0.2 8 0.4 15 0.5 
Multiple Myeloma 1384 1.6 1145 1.5 119 2.6 33 1.6 62 1.9 
Non-Hodgkin Lymphoma 3902 4.4 3436 4.5 165 3.7 81 3.8 174 5.3 
Oral Cavity & Pharynx 3256 3.7 2869 3.8 129 2.9 105 5.0 128 3.9 
Pancreas 2413 2.7 2160 2.8 122 2.7 42 2.0 72 2.2 
Prostate 21290 24.2 17259 22.7 1732 38.5 358 17.0 970 29.7 
Stomach 1633 1.9 1294 1.7 127 2.8 75 3.6 121 3.7 
Testis 1021 1.2 907 1.2 17 0.4 19 0.9 60 1.8 
Thyroid 1780 2.0 1506 2.0 62 1.4 101 4.8 68 2.1 
Urinary Bladder 6726 7.6 6306 8.3 122 2.7 82 3.9 118 3.6 
Other Sites 7078 8.0 6183 8.1 326 7.2 197 9.3 269 8.2 
 
                                                 
1 Race/ethnicity categories are mutually exclusive.  Cases are only included in one race/ethnicity category. 
2 The number of cases for all races is not the sum of cases by race/ethnicity.  3Breast in situ cases are excluded from ‘All Sites’ and breast cancer counts. 
 
Source:  Massachusetts Cancer Registry 
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Table 12. 
NUMBER AND PERCENTAGE OF INCIDENT CASES FOR SELECTED CANCER SITES BY RACE/ETHNICITY1 
Massachusetts, 2010-2014 
FEMALES 
 
  All Races2 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Cancer Site / Type Cases % of Cases Cases % of Cases Cases % of Cases Cases % of Cases Cases % of Cases 
All Sites 94299 100.0 82633 100.0 4310 100.0 2555 100.0 3648 100.0 
Brain & Other Nervous System 1133 1.2 977 1.2 46 1.1 39 1.5 62 1.7 
Breast3 28065 29.8 24764 30.0 1286 29.8 811 31.7 1030 28.2 
Bronchus & Lung 13091 13.9 12056 14.6 484 11.2 244 9.5 260 7.1 
Cervix Uteri 958 1.0 692 0.8 91 2.1 64 2.5 100 2.7 
Colon / Rectum 7355 7.8 6385 7.7 405 9.4 220 8.6 271 7.4 
Corpus Uteri & Uterus, NOS 6260 6.6 5552 6.7 276 6.4 117 4.6 243 6.7 
Esophagus 489 0.5 441 0.5 20 0.5 11 0.4 14 0.4 
Hodgkin Lymphoma 461 0.5 383 0.5 15 0.3 11 0.4 49 1.3 
Kidney & Renal Pelvis 2221 2.4 1936 2.3 122 2.8 37 1.4 104 2.9 
Larynx 311 0.3 280 0.3 15 0.3 5 0.2 8 0.2 
Leukemia 2061 2.2 1750 2.1 86 2.0 65 2.5 105 2.9 
Liver & Intrahepatic Bile Ducts 822 0.9 634 0.8 54 1.3 67 2.6 60 1.6 
Melanoma of Skin 3520 3.7 3233 3.9 13 0.3 9 0.4 35 1.0 
Multiple Myeloma 1139 1.2 874 1.1 148 3.4 21 0.8 77 2.1 
Non-Hodgkin Lymphoma 3537 3.8 3069 3.7 141 3.3 78 3.1 176 4.8 
Oral Cavity & Pharynx 1487 1.6 1293 1.6 54 1.3 56 2.2 64 1.8 
Ovary 2420 2.6 2140 2.6 92 2.1 79 3.1 79 2.2 
Pancreas 2543 2.7 2247 2.7 135 3.1 63 2.5 79 2.2 
Stomach 1001 1.1 763 0.9 88 2.0 68 2.7 74 2.0 
Thyroid 5323 5.6 4228 5.1 271 6.3 277 10.8 397 10.9 
Urinary Bladder 2498 2.6 2314 2.8 71 1.6 18 0.7 50 1.4 
Other Sites 7604 8.1 6622 8.0 397 9.2 195 7.6 311 8.5 
 
                                                 
1 Race/ethnicity categories are mutually exclusive.  Cases are only included in one race/ethnicity category. 
2 The number of cases for all races is not the sum of cases by race/ethnicity.  3Breast in situ cases are excluded from ‘All Sites’ and from breast cancer counts. 
 
 Source: Massachusetts Cancer Registry 
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Table 13. 
NUMBER AND PERCENTAGE OF INCIDENT CASES FOR SELECTED CANCER SITES BY RACE/ETHNICITY1 
Massachusetts, 2010-2014 
TOTAL2 
 
  All Races3 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Cancer Site / Type Cases % of Cases Cases % of Cases Cases % of Cases Cases % of Cases Cases % of Cases 
All Sites 182288 100.0 158794 100.0 8809 100.0 4665 100.0 6918 100.0 
Brain & Other Nervous System 2485 1.4 2171 1.4 93 1.1 66 1.4 133 1.9 
Breast4 28310 15.5 24981 15.7 1295 14.7 823 17.6 1036 15.0 
Bronchus & Lung 25043 13.7 22840 14.4 996 11.3 585 12.5 527 7.6 
Cervix Uteri 958 0.5 692 0.4 91 1.0 64 1.4 100 1.4 
Colon / Rectum 14694 8.1 12747 8.0 786 8.9 455 9.8 538 7.8 
Corpus Uteri & Uterus, NOS 6260 3.4 5552 3.5 276 3.1 117 2.5 243 3.5 
Esophagus 2234 1.2 2053 1.3 78 0.9 47 1.0 40 0.6 
Hodgkin Lymphoma 1020 0.6 831 0.5 53 0.6 27 0.6 99 1.4 
Kidney & Renal Pelvis 6030 3.3 5276 3.3 304 3.5 109 2.3 271 3.9 
Larynx 1328 0.7 1174 0.7 62 0.7 16 0.3 58 0.8 
Leukemia 4830 2.6 4168 2.6 193 2.2 124 2.7 215 3.1 
Liver & Intrahepatic Bile Ducts 3192 1.8 2391 1.5 242 2.7 267 5.7 259 3.7 
Melanoma of Skin 7863 4.3 7298 4.6 21 0.2 17 0.4 50 0.7 
Multiple Myeloma 2523 1.4 2019 1.3 267 3.0 54 1.2 139 2.0 
Non-Hodgkin Lymphoma 7440 4.1 6506 4.1 306 3.5 159 3.4 350 5.1 
Oral Cavity & Pharynx 4743 2.6 4162 2.6 183 2.1 161 3.5 192 2.8 
Ovary 2421 1.3 2141 1.3 92 1.0 79 1.7 79 1.1 
Pancreas 4956 2.7 4407 2.8 257 2.9 105 2.3 151 2.2 
Prostate 21290 11.7 17259 10.9 1732 19.7 358 7.7 970 14.0 
Stomach 2634 1.4 2057 1.3 215 2.4 143 3.1 195 2.8 
Testis 1021 0.6 907 0.6 17 0.2 19 0.4 60 0.9 
Thyroid 7104 3.9 5734 3.6 334 3.8 378 8.1 465 6.7 
Urinary Bladder 9225 5.1 8621 5.4 193 2.2 100 2.1 168 2.4 
Other Sites 14684 8.1 12807 8.1 723 8.2 392 8.4 580 8.4 
                                                 
1 Race/ethnicity categories are mutually exclusive.  Cases are only included in one race/ethnicity category. 
2Total includes persons classified as a transsexual and persons of unknown sex.  3The number of cases for all races is not the sum of cases by race/ethnicity.         
4 Breast in situ cases are excluded from ‘All Sites’ and from breast cancer counts.  Source: Massachusetts Cancer Registry 
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Table 14. 
AGE-ADJUSTED1 INCIDENCE RATES2 AND 95% CONFIDENCE LIMITS (95% CL)  
FOR SELECTED CANCER SITES BY RACE/ETHNICITY3 
Massachusetts, 2010-2014 
MALES 
 
  All Races White, non-Hispanics Black, non-Hispanics Asian, non-Hispanics Hispanics 
Cancer Site / Type Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL 
All Sites 505.7 502.3-509.2 506.7 503.0-510.3 537.9 521.0-554.9 317.2 302.8-331.7 398.8 383.1-414.5 
Brain & Other Nervous System 8.0 7.6-8.5 8.6 8.1-9.1 4.8 3.4-6.3 3.2 1.9-4.6 6.1 4.3-7.9 
Breast 1.4 1.2-1.6 1.5 1.3-1.7 * * * * * * 
Breast in situ4 0.1 0.1-0.2 * * * * * * * * 
Bronchus & Lung 70.8 69.5-72.1 72.5 71.1-73.9 69.7 63.2-76.2 58.5 51.9-65.1 39.7 34.4-45.0 
Colon / Rectum 43.0 42.0-44.0 43.0 41.9-44.1 46.8 41.7-51.9 34.5 29.8-39.1 36.2 31.1-41.2 
Esophagus 9.9 9.4-10.4 10.4 9.9-11.0 7.5 5.4-9.5 5.8 3.8-7.9 4.2 2.4-5.9 
Hodgkin Lymphoma 3.4 3.1-3.7 3.5 3.2-3.8 3.4 2.3-4.5 * * 3.7 2.4-5.0 
Kidney & Renal Pelvis 21.6 20.9-22.3 22.2 21.4-23.0 21.1 17.8-24.4 10.1 7.6-12.5 17.7 14.6-20.8 
Larynx 5.7 5.3-6.0 5.7 5.3-6.1 5.9 4.1-7.7 * * 6.0 4.1-7.9 
Leukemia 16.6 16.0-17.3 17.0 16.3-17.7 11.7 9.3-14.1 8.3 6.0-10.6 11.3 8.7-13.9 
Liver & Intrahepatic Bile Ducts 12.9 12.4-13.4 11.0 10.5-11.6 20.0 17.0-23.1 28.5 24.3-32.7 23.0 19.4-26.6 
Melanoma of Skin 25.5 24.7-26.3 27.8 26.9-28.7 * * * * * * 
Multiple Myeloma 8.0 7.6-8.5 7.6 7.2-8.1 15.6 12.6-18.6 5.0 3.2-6.8 7.4 5.3-9.4 
Non-Hodgkin Lymphoma 23.0 22.3-23.7 23.5 22.7-24.3 18.1 15.1-21.1 11.0 8.5-13.6 19.5 16.1-22.9 
Oral Cavity & Pharynx 17.8 17.2-18.5 18.3 17.6-18.9 14.6 11.9-17.3 14.0 11.2-16.8 15.7 12.6-18.8 
Pancreas 14.0 13.5-14.6 14.3 13.7-14.9 16.6 13.4-19.8 6.7 4.5-8.9 9.8 7.2-12.4 
Prostate 114.4 112.8-115.9 106.3 104.7-108.0 198.5 188.6-208.5 56.7 50.5-62.8 123.1 114.5-131.6 
Stomach 9.6 9.2-10.1 8.8 8.3-9.3 16.9 13.7-20.1 11.9 9.0-14.8 16.2 12.9-19.5 
Testis 6.4 6.0-6.8 7.7 7.2-8.2 * * * * 3.3 2.4-4.2 
Thyroid 10.3 9.8-10.8 10.7 10.1-11.3 6.6 4.9-8.4 11.3 9.0-13.6 5.5 4.1-6.9 
Urinary Bladder 40.6 39.6-41.5 42.9 41.9-44.0 17.0 13.8-20.3 14.4 11.1-17.7 17.6 13.9-21.2 
 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population.   
2 per 100,000     
3 Race/ethnicity categories are mutually exclusive. Cases are only included in one race/ethnicity category.  4 Breast in situ is excluded from ‘All Sites’. 
*An age-adjusted incidence rate was not calculated when there were fewer than 20 cases. 
 
Source: Massachusetts Cancer Registry 
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Table 15. 
AGE-ADJUSTED1 INCIDENCE RATES2 AND 95% CONFIDENCE LIMITS (95% CL) 
FOR SELECTED CANCER SITES BY RACE/ETHNICITY3 
Massachusetts, 2010-2014 
FEMALES 
 
  All Races White, non-Hispanics Black, non-Hispanics Asian, non-Hispanics Hispanics 
Cancer Site / Type Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL 
All Sites 450.4 447.4-453.3 463.4 460.1-466.7 396.2 384.2-408.3 304.0 291.7-316.3 326.0 314.6-337.5 
Brain & Other Nervous System 5.9 5.5-6.2 6.2 5.8-6.6 4.0 2.8-5.1 4.3 2.9-5.6 4.9 3.5-6.3 
Breast 136.3 134.7-137.9 142.3 140.5-144.2 116.4 110.0-122.9 90.2 83.8-96.6 88.4 82.7-94.2 
Breast in situ4 42.5 41.6-43.4 44.4 43.3-45.4 40.1 36.3-43.9 30.1 26.5-33.7 30.7 27.5-34.0 
Bronchus & Lung 60.7 59.7-61.8 64.1 62.9-65.2 46.8 42.6-51.1 33.7 29.3-38.0 28.4 24.7-32.0 
Cervix Uteri 5.2 4.9-5.6 4.8 4.4-5.2 8.2 6.5-9.9 6.9 5.1-8.6 8.4 6.6-10.2 
Colon / Rectum 33.7 32.9-34.5 33.7 32.8-34.6 37.2 33.5-40.9 28.5 24.6-32.4 27.2 23.8-30.7 
Corpus Uteri & Uterus, NOS 29.0 28.3-29.7 30.2 29.3-31.0 24.8 21.8-27.8 13.2 10.7-15.7 21.2 18.4-24.0 
Esophagus 2.2 2.0-2.4 2.3 2.1-2.5 1.8 1.0-2.5 * * * * 
Hodgkin Lymphoma 2.6 2.3-2.8 2.8 2.5-3.1 * * * * 3.3 2.3-4.4 
Kidney & Renal Pelvis 10.7 10.2-11.1 10.9 10.4-11.4 11.1 9.1-13.1 4.8 3.2-6.4 8.9 7.1-10.8 
Larynx 1.4 1.3-1.6 1.5 1.3-1.7 1.4 0.7-2.1 * * * * 
Leukemia 10.0 9.6-10.5 10.0 9.5-10.5 7.8 6.1-9.4 7.2 5.4-9.1 8.5 6.7-10.4 
Liver & Intrahepatic Bile Ducts 3.7 3.5-4.0 3.3 3.0-3.6 4.7 3.4-6.0 9.2 6.9-11.5 6.7 4.9-8.5 
Melanoma of Skin 17.3 16.7-17.9 19.3 18.6-20.0 * * * * 3.0 1.9-4.1 
Multiple Myeloma 5.2 4.9-5.5 4.5 4.2-4.8 14.2 11.9-16.5 2.8 1.6-4.1 7.5 5.7-9.2 
Non-Hodgkin Lymphoma 16.5 15.9-17.0 16.6 16.0-17.2 12.8 10.6-14.9 9.5 7.3-11.7 16.8 14.1-19.5 
Oral Cavity & Pharynx 6.9 6.6-7.3 6.9 6.6-7.3 4.6 3.4-5.9 7.3 5.3-9.3 6.4 4.7-8.1 
Ovary 11.5 11.0-12.0 12.0 11.4-12.5 8.2 6.5-9.9 9.0 6.9-11.1 6.6 5.1-8.2 
Pancreas 11.3 10.8-11.7 11.3 10.9-11.8 13.0 10.7-15.2 8.9 6.6-11.2 8.0 6.1-9.9 
Stomach 4.6 4.3-4.9 3.9 3.6-4.2 8.6 6.7-10.4 8.8 6.6-11.0 7.2 5.4-8.9 
Thyroid 29.2 28.4-30.0 29.5 28.5-30.4 23.4 20.6-26.2 27.7 24.3-31.0 27.5 24.6-30.3 
Urinary Bladder 11.3 10.8-11.7 11.9 11.4-12.4 7.2 5.5-8.9 2.5 1.3-3.7 5.5 3.9-7.2 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 
3 Race/ethnicity categories are mutually exclusive. Cases are only included in one race/ethnicity category.  4 Breast in situ cases are excluded from ‘All Sites’. 
* An age-adjusted incidence rate was not calculated when there were fewer than 20 cases. 
 
Source: Massachusetts Cancer Registry 
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Table 16. 
AGE-ADJUSTED1 INCIDENCE RATES2 AND 95% CONFIDENCE LIMITS (95% CL)  
FOR SELECTED CANCER SITES BY RACE/ETHNICITY3 
Massachusetts, 2010-2014 
 TOTAL 
 
  All Races White, non-Hispanics Black, non-Hispanics Asian, non-Hispanics Hispanics 
Cancer Site / Type Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL 
All Sites 471.1 468.9-473.3 478.5 476.0-480.9 453.4 443.6-463.2 308.5 299.2-317.9 354.3 345.0-363.6 
Brain & Other Nervous System 6.9 6.6-7.1 7.3 7.0-7.6 4.3 3.4-5.2 3.8 2.8-4.7 5.5 4.4-6.6 
Breast --5 -- -- -- -- -- -- -- -- -- 
Breast in situ4 -- -- -- -- -- -- -- -- -- -- 
Bronchus & Lung 64.7 63.8-65.5 67.3 66.4-68.2 55.7 52.1-59.3 44.7 40.9-48.5 33.0 29.9-36.0 
Cervix Uteri -- -- -- -- -- -- -- -- -- -- 
Colon / Rectum 37.8 37.2-38.4 37.8 37.2-38.5 41.0 38.0-44.0 31.3 28.3-34.4 30.8 27.9-33.7 
Corpus Uteri & Uterus, NOS -- -- -- -- -- -- -- -- -- -- 
Esophagus 5.6 5.4-5.9 5.9 5.7-6.2 4.0 3.1-5.0 3.4 2.4-4.5 2.6 1.7-3.5 
Hodgkin Lymphoma 3.0 2.8-3.1 3.1 2.9-3.4 2.3 1.6-2.9 1.1 0.7-1.6 3.5 2.7-4.3 
Kidney & Renal Pelvis 15.7 15.3-16.1 16.1 15.6-16.5 15.4 13.6-17.1 7.2 5.8-8.7 12.7 11.1-14.4 
Larynx 3.3 3.1-3.5 3.4 3.2-3.6 3.3 2.5-4.2 * * 3.0 2.2-3.9 
Leukemia 12.9 12.5-13.3 13.1 12.7-13.5 9.4 8.1-10.8 7.6 6.2-9.0 9.7 8.2-11.2 
Liver & Intrahepatic Bile Ducts 7.9 7.6-8.2 6.8 6.5-7.1 11.4 9.9-12.9 18.2 15.9-20.5 13.9 12.1-15.8 
Melanoma of Skin 20.6 20.2-21.1 22.8 22.2-23.3 1.1 0.6-1.6 * * 2.4 1.6-3.2 
Multiple Myeloma 6.4 6.2-6.7 5.9 5.6-6.1 14.7 12.9-16.6 3.8 2.8-4.9 7.4 6.1-8.8 
Non-Hodgkin Lymphoma 19.3 18.9-19.8 19.7 19.2-20.1 15.1 13.4-16.9 10.3 8.6-11.9 18.0 15.9-20.1 
Oral Cavity & Pharynx 12.0 11.6-12.3 12.2 11.9-12.6 8.9 7.6-10.3 10.5 8.8-12.2 10.4 8.8-12.1 
Ovary -- -- -- -- -- -- -- -- -- -- 
Pancreas 12.5 12.2-12.9 12.7 12.3-13.1 14.6 12.8-16.5 7.9 6.3-9.5 8.7 7.2-10.2 
Prostate -- -- -- -- -- -- -- -- -- -- 
Stomach 6.8 6.5-7.0 6.0 5.8-6.3 11.9 10.3-13.6 10.2 8.4-11.9 10.9 9.2-12.6 
Testis -- -- -- -- -- -- -- -- -- -- 
Thyroid 20.0 19.6-20.5 20.3 19.8-20.9 15.6 13.9-17.4 20.0 17.9-22.1 17.2 15.5-18.9 
Urinary Bladder 23.7 23.2-24.2 25.1 24.6-25.7 11.2 9.5-12.8 7.8 6.2-9.4 10.4 8.7-12.2 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population.  
2 per 100,000  
3 Race/ethnicity categories are mutually exclusive.  Cases are only included in one race/ethnicity category.  4 Breast in situ cases are excluded from ‘All Sites’.     
5 Dashes indicate cancers found in only one sex or predominantly in one sex (breast cancer).  * An age-adjusted incidence rate was not calculated when there 
were fewer than 20 cases.  Source: Massachusetts Cancer Registry    
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Table 17. 
FIVE LEADING CANCER MORTALITY RATES BY RACE/ETHNICITY AND SEX 
Massachusetts, 2010-2014 
 
 
MALES 
 
 
AGE-ADJUSTED1 MORTALITY RATE2 
RANK White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
1 
Bronchus & Lung     
51.7   
Bronchus & Lung     
50.2       
Bronchus & Lung 
37.7  
Bronchus & Lung  
24.2  
2 
Prostate                     
18.1                      
Prostate                    
39.8                     
Liver & Intrahepatic 
Bile Duct              
21.4               
Prostate                 
15.8                  
3 
Colon/Rectum           
15.7           
Colon/Rectum         
17.2         
Colon/Rectum        
8.7            
Liver & Intrahepatic 
Bile Duct             
12.5             
4 
Pancreas                   
12.5                    
Liver & Intrahepatic 
Bile Duct                 
13.6                   
Prostate                  
7.2                   
Colon/Rectum       
10.4      
5 
Leukemia                   
9.1                          
Pancreas                   
13.6                     
Pancreas                 
5.8                              
Pancreas                 
8.1                  
 
 
FEMALES 
 
 
AGE-ADJUSTED1 MORTALITY RATE2 
RANK White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
1 
Bronchus & Lung      
39.2  
Bronchus & Lung      
27.9        
Bronchus & Lung       
17.5      
Bronchus & Lung  
12.0  
2 
Breast                        
18.8                        
Breast                       
19.7                      
Colon/Rectum             
8.9            
Breast             
10.5  
3 Colon/Rectum            
10.8             
Colon/Rectum          
13.9           
Breast                         
7.9                          
Colon/Rectum  
9.2                 
4 
Pancreas                      
9.8                      
Pancreas                    
10.1                     
Pancreas                      
7.1                      
Pancreas          
6.3            
5 
Ovary                           
7.7                           
Corpus Uteri & Uterus, 
NOS                            
7.7                             
Liver & Intrahepatic 
Bile Duct                    
6.6                     
Liver & 
Intrahepatic Bile 
Duct                    
4.6                                  
 
 
 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000  
 
Source:  Massachusetts Vital Statistics 
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Table 18. 
NUMBER AND PERCENTAGE OF DEATHS FOR SELECTED CANCER SITES BY RACE/ETHNICITY1 
Massachusetts, 2010-2014 
MALES 
 
  All Races2 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Cancer Site / Type Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths 
All Sites 32258 100.0 29057 100.0 1487 100.0 715 100.0 865 100.0 
Brain & Other Nervous System 894 2.8 827 2.8 27 1.8 11 1.5 23 2.7 
Breast 64 0.2 62 0.2 2 0.1 0 0.0 0 0.0 
Bronchus & Lung 8555 26.5 7789 26.8 359 24.1 211 29.5 164 19.0 
Colon / Rectum 2590 8.0 2332 8.0 132 8.9 54 7.5 61 7.1 
Esophagus 1485 4.6 1388 4.8 49 3.3 21 2.9 21 2.4 
Hodgkin Lymphoma 57 0.2 47 0.2 2 0.1 2 0.3 6 0.7 
Kidney & Renal Pelvis 818 2.5 754 2.6 32 2.1 8 1.1 22 2.5 
Larynx 272 0.8 239 0.8 13 0.9 5 0.7 13 1.5 
Leukemia 1430 4.4 1313 4.5 42 2.8 25 3.5 45 5.2 
Liver & Intrahepatic Bile Ducts 1775 5.5 1398 4.8 120 8.1 140 19.6 107 12.4 
Melanoma of Skin 687 2.1 672 2.3 5 0.3 1 0.1 5 0.6 
Multiple Myeloma 640 2.0 551 1.9 52 3.5 12 1.7 22 2.5 
Non-Hodgkin Lymphoma 1116 3.5 1021 3.5 40 2.7 15 2.1 34 3.9 
Oral Cavity & Pharynx 668 2.1 576 2.0 40 2.7 22 3.1 26 3.0 
Pancreas 2113 6.6 1915 6.6 95 6.4 34 4.8 59 6.8 
Prostate 3001 9.3 2647 9.1 223 15.0 32 4.5 86 9.9 
Stomach 670 2.1 535 1.8 46 3.1 33 4.6 53 6.1 
Testis 22 0.1 21 0.1 0 0.0 0 0.0 1 0.1 
Thyroid 103 0.3 96 0.3 3 0.2 2 0.3 2 0.2 
Urinary Bladder 1318 4.1 1258 4.3 28 1.9 13 1.8 4 3.0 
Other Sites 3980 12.3 3616 12.4 177 11.9 74 10.3 100 11.6 
 
                                                 
1 Race/ethnicity categories are mutually exclusive.  Deaths are only included in one race/ethnicity category. 
2 The number of deaths for all races is not the sum of deaths by race/ethnicity. 
 
Source:  Massachusetts Vital Statistics 
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Table 19. 
NUMBER AND PERCENTAGE OF DEATHS FOR SELECTED CANCER SITES BY RACE/ETHNICITY1 
Massachusetts, 2010-2014 
FEMALES 
 
  All Races2 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Cancer Site / Type Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths 
All Sites 31413 100.0 28497 100.0 1423 100.0 585 100.0 798 100.0 
Brain & Other Nervous System 699 2.2 643 2.3 18 1.3 18 3.1 19 2.4 
Breast 4142 13.2 3733 13.1 213 15.0 64 10.9 117 14.7 
Bronchus & Lung 8337 26.5 7801 27.4 290 20.4 119 20.3 104 13.0 
Cervix Uteri 251 0.8 199 0.7 23 1.6 6 1.0 19 2.4 
Colon / Rectum 2640 8.4 2336 8.2 147 10.3 63 10.8 83 10.4 
Corpus Uteri & Uterus, NOS 1029 3.3 885 3.1 82 5.8 20 4.5 36 4.5 
Esophagus 372 1.2 338 1.2 13 0.9 8 1.4 11 1.4 
Hodgkin Lymphoma 48 0.1 44 0.1 0 0.0 1 0.2 3 0.4 
Kidney & Renal Pelvis 480 1.5 453 1.6 12 0.8 2 0.3 9 1.1 
Larynx 93 0.3 88 0.3 2 0.1 1 0.2 2 0.3 
Leukemia 1100 3.5 987 3.5 52 3.7 17 2.9 40 5.0 
Liver & Intrahepatic Bile Ducts 799 2.5 668 2.3 40 2.8 50 8.6 40 5.0 
Melanoma of Skin 420 1.3 409 1.4 4 0.3 2 0.3 4 0.5 
Multiple Myeloma 635 2.0 536 1.9 67 4.7 5 0.9 24 3.0 
Non-Hodgkin Lymphoma 1019 3.2 931 3.3 33 2.3 19 3.3 34 4.3 
Oral Cavity & Pharynx 311 1.0 281 1.0 8 0.6 9 1.5 11 1.4 
Ovary 1656 5.3 1528 5.4 69 4.8 28 4.8 26 3.3 
Pancreas 2274 7.2 2057 7.2 105 7.4 46 7.9 58 7.3 
Stomach 541 1.7 438 1.5 40 2.8 26 4.4 32 4.0 
Thyroid 109 0.4 90 0.3 7 0.5 4 0.7 8 1.0 
Urinary Bladder 614 2.0 588 2.1 18 1.3 3 0.5 5 0.6 
Other Sites 3844 12.2 3464 12.2 180 12.7 74 12.7 113 14.2 
 
                                                 
1 Race/ethnicity categories are mutually exclusive.  Deaths are only included in one race/ethnicity category. 
2 The number of deaths for all races is not the sum of deaths by race/ethnicity. 
 
 Source: Massachusetts Vital Statistics 
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Table 20. 
NUMBER AND PERCENTAGE OF DEATHS FOR SELECTED CANCER SITES BY RACE/ETHNICITY1 
Massachusetts, 2010-2014 
TOTAL 
 
  All Races2 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Cancer Site / Type Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths Deaths % of Deaths 
All Sites 63671 100.0 57554 100.0 2910 100.0 1300 100.0 1663 100.0 
Brain & Other Nervous System 1593 2.5 1470 2.6 45 1.6 29 2.2 42 2.5 
Breast 4206 6.6 3795 6.6 215 7.4 64 4.9 117 7.0 
Bronchus & Lung 16892 26.5 15590 27.1 649 22.3 330 25.4 268 16.1 
Cervix Uteri 251 0.4 23 0.8 23 0.8 6 0.5 19 1.1 
Colon / Rectum 5230 8.2 4668 8.1 279 9.6 117 9.0 144 8.7 
Corpus Uteri & Uterus, NOS 1029 1.6 82 2.8 82 2.8 20 1.5 36 2.2 
Esophagus 1857 2.9 1726 3.0 62 2.1 29 2.2 32 1.9 
Hodgkin Lymphoma 105 0.2 91 0.2 2 0.1 3 0.2 9 0.5 
Kidney & Renal Pelvis 1298 2.0 1207 2.1 44 1.5 10 0.8 31 1.9 
Larynx 365 0.6 327 0.6 15 0.5 6 0.5 15 0.9 
Leukemia 2530 4.0 2300 4.0 94 3.2 42 3.2 85 5.1 
Liver & Intrahepatic Bile Ducts 2574 4.0 2066 3.6 160 5.5 190 14.6 147 8.8 
Melanoma of Skin 1107 1.7 1081 1.9 9 0.3 3 0.2 9 0.5 
Multiple Myeloma 1275 2.0 1087 1.9 119 4.1 17 1.3 46 2.8 
Non-Hodgkin Lymphoma 2135 3.4 1952 3.4 73 2.5 34 2.6 68 4.1 
Oral Cavity & Pharynx 979 1.5 857 1.5 48 1.7 31 2.4 37 2.2 
Ovary 1656 2.6 1528 2.7- 69 2.4 28 2.2 26 1.6 
Pancreas 4387 6.9 3972 6.9 200 6.9 80 6.2 117 7.0 
Prostate 3001 4.7 2647 4.6 223 7.7 32 2.5 86 5.2 
Stomach 1211 1.9 973 1.7 86 3.0 59 4.5 85 5.1 
Testis 22 0.03 21 0.5 0 0.0 0 0.0 1 0.0 
Thyroid 212 0.3 186 3.2 10 0.3 6 0.5 10 0.6 
Urinary Bladder 1932 3.0 1846 3.2 46 1.6 16 1.2 20 1.2 
Other Sites 7824 12.3 7080 12.3 357 12.3 148 11.4 213 12.8 
 
                                                 
1 Race/ethnicity categories are mutually exclusive.  Deaths are only included in one race/ethnicity category. 
2 The number of deaths for all races is not the sum of deaths by race/ethnicity. 
 
Source: Massachusetts Vital Statistics 
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Table 21. 
AGE-ADJUSTED1 MORTALITY RATES2 AND 95% CONFIDENCE LIMITS (95% CL)  
FOR SELECTED CANCER SITES BY RACE/ETHNICITY3 
Massachusetts, 2010-2014 
MALES 
 
  All Races White, non-Hispanics Black, non-Hispanics Asian, non-Hispanics Hispanics 
Cancer Site / Type Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL 
All Sites 190.2 188.1-192.2 193.6 191.4-195.8 210.1 199.4-220.8 121.5 112.6-130.4 125.5 117.2-133.9 
Brain & Other Nervous System 5.1 4.7-5.4 5.5 5.1-5.8 2.7 1.7-3.8 * * 2.4 1.4-3.4 
Breast 0.4 0.3-0.5 0.4 0.3-0.5 * * * * * * 
Bronchus & Lung 50.3 49.3-51.4 51.7 50.6-52.9 50.2 45.0-55.4 37.7 32.6-42.8 24.2 20.5-27.9 
Colon / Rectum 15.3 14.8-15.9 15.6 15.0-16.3 17.2 14.3-20.2 8.7 6.4-11.0 10.4 7.8-13.0 
Esophagus 8.4 8.0-8.8 8.9 8.4-9.4 6.5 4.7-8.3 4.4 2.5-6.2 3.1 1.8-4.5 
Hodgkin Lymphoma 0.3 0.3-0.4 0.3 0.2-0.5 * * * * * * 
Kidney & Renal Pelvis 4.7 4.4-5.0 4.9 4.5-5.2 5.0 3.3-6.8 * * 2.5 1.5-3.6 
Larynx 1.6 1.4-1.8 1.6 1.4-1.8 * * * * * * 
Leukemia 8.7 8.3-9.2 9.1 8.6-9.5 6.0 4.2-7.8 4.3 2.6-6.0 6.2 4.4-8.0 
Liver & Intrahepatic Bile Ducts 9.8 9.3-10.3 8.8 8.3-9.3 13.6 11.2-16.1 21.4 17.9-25.0 12.5 10.1-14.8 
Melanoma of Skin 4.1 3.7-4.4 4.5 4.2-4.9 * * * * * * 
Multiple Myeloma 3.8 3.5-4.1 3.7 3.4-4.0 7.3 5.3-9.3 * * 4.2 2.4-6.0 
Non-Hodgkin Lymphoma 6.8 6.4-7.2 7.0 6.5-7.4 5.2 3.6-6.9 * * 4.2 2.8-5.6 
Oral Cavity & Pharynx 3.7 3.5-4.0 3.7 3.4-4.0 4.9 3.4-6.4 3.1 1.8-4.4 3.7 2.3-5.1 
Pancreas 12.2 11.7-12.7 12.5 12.0-13.1 13.6 10.9-16.3 5.8 3.8-7.7 8.1 6.0-10.1 
Prostate 18.6 17.9-19.3 18.1 17.5-18.8 39.8 34.6-45.0 7.2 4.7-9.8 15.8 12.5-19.2 
Stomach 4.0 3.7-4.3 3.6 3.3-3.9 6.6 4.7-8.6 5.1 3.4-6.9 7.6 5.6-9.7 
Testis 0.1 0.1-0.2 0.1 0.1-0.2 * * * * * * 
Thyroid 0.6 0.5-0.7 0.6 0.5-0.8 * * * * * * 
Urinary Bladder 8.1 7.6-8.5 8.5 8.1-9.0 4.8 3.0-6.6 * * * * 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population.   
2 per 100,000     
3 Race/ethnicity categories are mutually exclusive. Deaths are only included in one race/ethnicity category. 
*An age-adjusted mortality rate was not calculated when there were fewer than 20 deaths. 
 
Source: Massachusetts Vital Statistics 
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Table 22. 
AGE-ADJUSTED1 MORTALITY RATES2 AND 95% CONFIDENCE LIMITS (95% CL) 
FOR SELECTED CANCER SITES BY RACE/ETHNICITY3 
Massachusetts, 2010-2014 
FEMALES 
 
  All Races White, non-Hispanics Black, non-Hispanics Asian, non-Hispanics Hispanics 
Cancer Site / Type Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL 
All Sites 135.9 134.4-137.4 140.0 138.3-141.6 135.4 128.3-142.4 80.7 74.2-87.2 86.5 90.5-92.5 
Brain & Other Nervous System 3.2 3.0-3.5 3.5 3.2-3.8 * * * * * * 
Breast 18.2 17.7-18.8 18.8 18.2-19.4 19.7 17.1-22.4 7.9 5.9-9.8 10.5 8.6-12.4 
Bronchus & Lung 36.9 36.1-37.6 39.2 38.4-40.1 27.9 24.7-31.2 17.5 14.4-20.7 12.0 9.7-14.3 
Cervix Uteri 1.2 1.0-1.3 1.1 1.0-1.3 2.0 1.2-2.8 * * * * 
Colon / Rectum 10.9 10.5-11.3 10.8 10.4-11.3 13.9 11.6-16.1 8.9 6.7-11.1 9.2 7.2-11.2 
Corpus Uteri & Uterus, NOS 4.4 4.2-4.7 4.3 4.0-4.6 7.7 6.0-9.4 2.6 1.4-3.7 4.1 2.7-5.4 
Esophagus 1.6 1.4-1.7 1.6 1.5-1.8 * * * * * * 
Hodgkin Lymphoma 0.2 0.2-0.3 0.2 0.2-0.3 * * * * * * 
Kidney & Renal Pelvis 2.0 1.8-2.2 2.1 2.0-2.3 * * * * * * 
Larynx 0.4 0.3-0.5 0.4 0.3-0.5 * * * * * * 
Leukemia 4.8 4.5-5.1 4.8 4.5-5.1 5.2 3.8-6.6 * * 4.3 3.0-5.7 
Liver & Intrahepatic Bile Ducts 3.5 3.2-3.7 3.3 3.0-3.5 3.7 2.6-4.9 6.6 4.8-8.5 4.6 3.2-6.1 
Melanoma of Skin 1.9 1.7-2.0 2.1 1.9-2.3 * * * * * * 
Multiple Myeloma 2.6 2.4-2.8 2.5 2.3-2.7 6.5 5.0-8.1 * * 2.7 1.6-3.8 
Non-Hodgkin Lymphoma 4.2 4.0-4.5 4.3 4.0-4.6 3.1 2.0-4.2 * * 4.3 2.9-5.8 
Oral Cavity & Pharynx 1.3 1.2-1.5 1.3 1.2-1.5 * * * * * * 
Ovary 7.3 6.9-7.6 7.7 7.3-8.1 6.3 4.8-7.8 3.5 2.2-4.8 2.7 1.7-3.7 
Pancreas 9.6 9.2-10.0 9.8 9.4-10.3 10.1 8.1-12.0 7.1 5.0-9.1 6.3 4.7-7.9 
Stomach 2.3 2.1-2.5 2.0 1.8-2.2 3.9 2.7-5.1 3.5 2.1-4.8 3.1 2.0-4.2 
Thyroid 0.5 0.4-0.5 0.4 0.3-0.5 * * * * * * 
Urinary Bladder 2.5 2.3-2.7 2.6 2.4-2.8 * * * * * * 
 
 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 
3 Race/ethnicity categories are mutually exclusive. Deaths are only included in one race/ethnicity category. 
* An age-adjusted mortality rate was not calculated when there were fewer than 20 deaths. 
 
Source: Massachusetts Vital Statistics 
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Table 23. 
AGE-ADJUSTED1 MORTALITY RATES2 AND 95% CONFIDENCE LIMITS (95% CL)  
FOR SELECTED CANCER SITES BY RACE/ETHNICITY3 
Massachusetts, 2010-2014 
TOTAL 
 
  All Races White, non-Hispanics Black, non-Hispanics Asian, non-Hispanics Hispanics 
Cancer Site / Type Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL Rates 95% CL 
All Sites 157.8 156.6-159.0 161.6 160.3-162.9 163.3 157.4-169.2 98.9 93.5-104.3 102.6 97.7-107.6 
Brain & Other Nervous System 4.1 3.9-4.3 4.4 4.2-4.6 2.2 1.5-2.8 1.8 1.2-2.5 2.1 1.5-2.7 
Breast - - - - - - - - - - 
Bronchus & Lung 42.4 41.7-43.0 44.3 43.6-45.0 36.7 33.9-39.5 26.4 23.6-29.3 17.2 15.1-19.2 
Cervix Uteri - - - - - - - - - -- 
Colon / Rectum 12.8 12.5-13.1 12.9 12.5-13.3 15.4 13.6-17.2 8.8 7.2-10.5 9.6 8.1-11.2 
Corpus Uteri & Uterus, NOS - - - - - - - - - - 
Esophagus 4.6 4.4-4.8 4.8 4.6-5.1 3.3 2.5-4.1 2.5 1.6-3.4 2.1 1.3-2.8 
Hodgkin Lymphoma 0.3 0.2-0.3 0.3 0.2-0.4 * * * * * * 
Kidney & Renal Pelvis 3.2 3.0-3.3 3.3 3.1-3.5 2.5 1.8-3.3 * * 1.7 1.1-2.2 
Larynx 0.9 0.8-1.0 0.9 0.8-1.0 * * * * * * 
Leukemia 6.4 6.1-6.6 6.6 6.3-6.8 5.3 4.3-6.4 3.1 2.1-4.0 5.1 4.0-6.2 
Liver & Intrahepatic Bile Ducts 6.3 6.1-6.6 5.7 5.5-6.0 8.1 6.8-9.3 13.4 11.5-15.3 8.1 6.8-9.5 
Melanoma of Skin 2.8 2.6-2.9 3.1 2.9-3.3 * * * * * * 
Multiple Myeloma 3.1 3.0-3.3 3.0 2.8-3.2 6.8 5.6-8.0 * * 3.3 2.3-4.2 
Non-Hodgkin Lymphoma 5.3 5.1-5.5 5.4 5.2-5.7 4.0 3.1-4.9 2.6 1.7-3.5 4.4 3.3-5.4 
Oral Cavity & Pharynx 2.4 2.3-2.6 2.4 2.2-2.6 2.5 1.8-3.2 2.1 1.4-2.8 2.3 1.5-3.0 
Ovary - - - - - - - - - - 
Pancreas 10.8 10.5-11.1 11.0 10.7-11.4 11.5 10.0-13.2 6.5 5.1-8.0 7.1 5.8-8.3 
Prostate - - - - - - - - - - 
Stomach 3.0 2.8-3.2 2.7 2.5-2.9 5.0 3.9-6.1 3.1 2.0-4.2 4.9 3.9-6.0 
Testis - - - - - - - - - - 
Thyroid 0.5 0.5-0.6 0.5 0.4-0.6 * * * * * * 
Urinary Bladder 4.7 4.5-4.9 5.0 4.8-5.2 2.9 2.0-3.7 * * 1.5 0.9-2.2 
                                                 
1 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2 per 100,000 
3 Race/ethnicity categories are mutually exclusive.  Deaths are only included in one race/ethnicity category. 
4Dashes indicate cancers found in only one sex or predominantly in one sex (breast cancer). 
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Table 24. 
   INCIDENCE RATES1 FOR SELECTED CANCER SITES BY SEX 
 Massachusetts (2010-2014 and U.S. (2009-2013)  
 
 MALES FEMALES 
Cancer Site / Type Massachusetts United States Massachusetts United States 
 Rate 95% CL  Rate 95% CL Rate 95% CL Rate 95% CL 
All Sites 505.7* 502.3-509.2 512.1 511.6-512.6 450.4* 447.4-453.3 418.46 418.0-418.9 
Brain & Other Nervous System 8.0 7.6-8.5 7.8 7.7-7.8 5.9 5.5-6.2 5.6 5.6-5.7 
Breast 1.4 1.2-1.6 1.3 1.3-1.4 136.3* 134.7-137.9 123.3 123.1-123.6 
Breast in situ2 0.1 0.1-0.2 N/A N/A 42.5* 41.6-43.4 31.0 30.9-31.1 
Bronchus & Lung 70.8* 69.5-72.1 75.0 74.8-75.2 60.7* 59.7-61.8 53.5 53.4-53.7 
Cervix Uteri -- -- -- -- 5.2* 4.9-5.6 7.6 7.6-7.7 
Colon / Rectum 43.0* 42.0-44.0 46.9 46.7-47.0 33.7* 32.9-34.5 35.6 35.5-35.7 
Corpus Uteri & Uterus, NOS -- -- -- -- 29.0* 28.3-29.7 25.6 25.5-25.7 
Esophagus 9.9* 9.4-10.4 8.1 8.1-8.2 2.2* 2.0-2.4 1.8 1.8-1.8 
Hodgkin Lymphoma 3.4 3.1-3.7 3.1 3.0-3.1 2.6 2.3-2.8 2.4 2.3-2.4 
Kidney & Renal Pelvis 21.6 20.9-22.3 21.7 21.6-21.8 10.7* 10.2-11.1 11.3 11.2-11.4 
Larynx 5.7* 5.3-6.0 6.2 6.1-6.2 1.4 1.3-1.6 1.4 1.4-1.4 
Leukemia 16.6 16.0-17.3 17.2 17.2-17.4 10.0 9.6-10.5 10.6 10.5-10.6 
Liver & Intrahepatic Bile Ducts 12.9* 12.4-13.4 11.8 11.7-11.9 3.7 3.5-4.0 4.0 4.0-4.1 
Melanoma of Skin 25.5 24.7-26.3 25.9 25.8-26.0 17.3* 16.7-17.9 16.1 16.0-16.2 
Multiple Myeloma 8.0 7.6-8.5 8.0 7.9-8.0 5.2 4.9-5.5 5.2 5.2-5.3 
Non-Hodgkin Lymphoma 23.0 22.3-23.7 23.0 22.9-23.1 16.5 15.9-17.0 15.9 15.8-16.0 
Oral Cavity & Pharynx 17.8 17.2-18.5 17.2 17.1-17.2 6.9* 6.6-7.3 6.3 6.3-6.4 
Ovary -- -- -- -- 11.5 11.0-12.0 11.6 11.6-11.7 
Pancreas 14.0 13.5-14.6 14.1 14.0-14.2 11.3 10.8-11.7 10.9 10.9-11.0 
Prostate 114.4* 112.8-115.9 123.2 123.0-123.5 -- -- -- -- 
Stomach 9.6 9.2-10.1 9.2 9.2-9.3 4.6 4.3-4.9 4.6 4.6-4.7 
Testis 6.4* 6.0-6.8 5.5 5.4-5.5 -- -- -- -- 
Thyroid 10.3* 9.8-10.8 7.0 7.0-7.1 29.2* 28.4-30.0 20.8 20.7-20.9 
Urinary Bladder 40.6* 39.6-41.5 36.2 36.0-36.3 11.3* 10.8-11.7 8.9 8.9-9.0 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________ 
 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2Breast in situ cases are excluded from “All Sites” and from breast cancer counts. 
N/A – not available 
* indicates that the Massachusetts incidence rate differed significantly from the national rate (p < 0.05). 
 Data Sources:  Massachusetts: Massachusetts Cancer Registry and United States: NAACCR Fast Stats: An interactive 
tool for quick access to key NAACCR cancer statistics.  North American Association of Central Cancer Registries.  
http://www.naaccr.org/. (Accessed on 3-8-2017) 
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Table 25. 
MORTALITY RATES1 FOR SELECTED CANCER SITES BY SEX 
Massachusetts and U.S. (2010-2014) 
 
 MALES FEMALES 
Cancer Site / Type Massachusetts United States Massachusetts United States 
 Rate 95% CL Rate 95% CL Rate 95% CL Rate 95% CL 
All Sites 190.2* 188.1-192.2 200.3 200.0-200.7 135.9* 134.4-137.4 142.0 141.7-142.2 
Brain & Other Nervous System 5.1 4.7-5.4 5.3 5.3-5.4 3.2 3.0-3.5 3.5 3.5-3.6 
Breast 0.4 0.3-0.5 0.3 0.3-0.3 18.2* 17.7-18.8 21.3 21.2-21.4 
Bronchus & Lung 50.3* 49.3-51.4 55.8 55.6-56.0 36.9 36.1-37.6 36.3 36.2-36.4 
Cervix Uteri - - - - 1.2* 1.0-1.3 2.3 2.3-2.3 
Colon / Rectum 15.3* 14.8-15.9 17.8 17.7-17.9 10.9* 10.5-11.3 12.7 12.6-12.7 
Corpus Uteri & Uterus, NOS - - - - 4.4 4.2-4.7 4.6 4.5-4.6 
Esophagus 8.4* 8.0-8.8 7.3 7.2-7.4 1.6 1.4-1.7 1.5 1.5-1.5 
Hodgkin Lymphoma 0.3 0.3-0.4 0.4 0.4-0.5 0.2 0.2-0.3 0.3 0.3-0.3 
Kidney & Renal Pelvis 4.7* 4.4-5.0 5.7 5.6-5.7 2.0* 1.8-2.2 2.5 2.4-2.5 
Larynx 1.6 1.4-1.8 1.9 1.8-1.9 0.4 0.3-0.5 0.4 0.4-0.4 
Leukemia 8.7 8.3-9.2 9.1 9.0-9.1 4.8 4.5-5.1 5.1 5.0-5.1 
Liver & Intrahepatic Bile Ducts 9.8 9.3-10.3 9.9 9.2-9.4 3.5 3.2-3.7 3.8 3.7-3.8 
Melanoma of Skin 4.1 3.7-4.4 4.0 4.0-4.0 1.9 1.7-2.0 1.7 1.6-1.7 
Multiple Myeloma 3.8* 3.5-4.1 4.4 4.3-4.4 2.6 2.4-2.8 2.8 2.8-2.8 
Non-Hodgkin Lymphoma 6.8* 6.4-7.2 7.6 7.5-7.6 4.2 4.0-4.5 4.6 4.5-4.6 
Oral Cavity & Pharynx 3.7 3.5-4.0 3.9 3.8-3.9 1.3 1.2-1.5 1.3 1.3-1.4 
Ovary - - - - 7.3 6.9-7.6 7.4 7.4-7.5 
Pancreas 12.2 11.7-12.7 12.6 12.5-12.7 9.6 9.2-10.0 9.6 9.5-9.6 
Prostate 18.6* 17.9-19.3 20.0 19.9-20.1 - - - - 
Stomach 4.0 3.7-4.3 4.4 4.3-4.4 2.3 2.1-2.5 2.3 2.3-2.4 
Testis 0.1* 0.1-0.2 0.3 0.3-0.3 - - - - 
Thyroid 0.6 0.5-0.7 0.5 0.5-0.5 0.5 0.4-0.5 0.5 0.5-0.5 
Urinary Bladder 8.1 7.6-8.5 7.6 7.5-7.7 2.5* 2.3-2.7 2.2 2.1-2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
__________________________________________________ 
 Rates are age-adjusted to the 2000 U.S. Standard Population. 
2Breast in situ cases are excluded from “All Sites” and from breast cancer counts. 
N/A – not applicable 
* indicates that the Massachusetts mortality rate differed significantly from the national rate (p < 0.05). 
 Data Sources:  Massachusetts: Massachusetts Vital Statistics and United States:  National Center for Health Statistics. 
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APPENDIX I 
 
ICD CODES USED FOR THIS REPORT  
 
 
Cancer Site/Type .……….C o d e s……….. 
 ICD-O-3* ICD-10** 
Brain & Other  
Nervous System 
C70.0-C72.9 
except 9590-9989 
C70-C72 
Breast 
 (includes in situ) 
C50.0 – C50.9 
except 9590 -9989 
C50 
Bronchus & Lung C34.0 – C34.9  
except 9590-9989 
 
C34 
Cervix Uteri C53.0 – C53.9 
except 9590-9989 
C53 
Colon/ Rectum C18.0-C18.9, 
C19.9, C20.9, 
C26.0 
except 9590-9989 
 
C18 – C20, C26.0 
Corpus Uteri  
& Uterus, NOS 
C54.0 – C54.9, 
C55.9 
except 9590 – 9989 
C54 – C55 
Esophagus C15.0-C15.9 
except 9590 – 9989 
C15 
Hodgkin Lymphoma C00.00 – C80.9  
(includes 9650-9667) 
 
C81 
Kidney &  
Renal Pelvis 
C64.9, C65.9 
except 9590-9989 
C64- C65 
Larynx C32.0 – C32.9 
except 9590- 9989 
C32 
Leukemia C00.0 – C80.9 
(includes 9733, 9742, 
9800 – 9820, 9826, 
9831 – 9948, 9963 – 9964) 
C42.0, C42.1, C42.4 
(includes 9823, 9827) 
C90.1, C91 – C95 
Liver and Intrahepatic 
Bile Ducts 
C22.0, C22.1 
except 9590 – 9989 
C22 
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Cancer Site/ Type ……….C o d e s……….. 
 ICD-O-3* ICD-10** 
Melanoma of Skin C44.0 – C44.9 
(includes 8720-8790) 
C43 
Multiple Myeloma C00.0-C80.9 
(includes 9731, 9732, 
9734) 
 
C90.0, C90.2 
Non – Hodgkin  
Lymphoma 
C00.0 – C80.9 
(includes 9590 – 9596, 
9670 – 9729) 
All sites except C42.0, 
C42.1, C42.4 
(includes 9823, 9827) 
 
C82 – C85, C96.3 
Oral Cavity  
& Pharynx 
C00.0 – C14.8 
except 9590 – 9989 
C00 – C14 
Ovary C56.9 
except 9590- 9989 
C56 
Pancreas C25.0 – C25.9 
except 9590 – 9989 
 
 
Prostate C61.9 
except 9590 – 9989 
C61 
Stomach C16.0 – C16.9 
except 9590- 9989 
C16 
Testis C62.0 – C62.9 
except 9590 – 9989 
C62 
Thyroid C73.9  
except 9590 – 9989 
C73 
Urinary Bladder 
(includes in situ) 
C67.0 – C67.9 
except 9590 – 9989 
 
C67 
 
 
* International Classification of Diseases for Oncology, 3d Ed. (includes codes added since 
publication) for incidence data 
** International Classification of Diseases, Tenth Revision (includes codes added since publication) 
for mortality data 
 
 
 
 - 52 - 
APPENDIX II: 
 
Population and Rate Changes 
 
The population estimates for 2010-2014 used in this report were produced by the National Center for 
Health Statistics (NCHS) in collaboration with the U.S. Census Bureau’s Population Estimation Program.  
The NCHS takes the Census Bureau population estimates file and reallocates the multiple race categories 
required by the 1997 Office of Management and Budget (OMB) specifications back into the four race 
categories specified in the 1977 OMB specifications so that the estimates will be compatible with previous 
years’ populations. (3)  The estimates are divided into mutually exclusive racial/ethnic categories similar to 
those of the MCR. 
 
Please note that the statewide age-adjusted rates published in this report cannot be compared with those 
published in reports prior to July 2007, because the overall population count and the age distribution of the 
population, which were based on the Census 2000 count, differ. 
 
The difference in the new population estimates is pronounced for Hispanics and black, non-Hispanics.  The 
Hispanic and black, non-Hispanic populations have increased 15% since 2000, while the overall state 
population has increased by 1%.  It is important to remember that both age-adjusted cancer incidence and 
cancer death rates are not a measure of the actual risk of cancer or of death from it.  Rather, age-adjusted 
rates are summary measures used to compare cancer incidence and mortality trends over time or among 
different populations whose age distributions differ.  For specific examples of the effect of new population 
estimates on age-adjusted rates, see Appendix II in the report Cancer Incidence and Mortality in 
Massachusetts 2000-2004: Statewide Report, available at www.mass.gov/dph/mcr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
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Appendix III 
    
POPULATION ESTIMATES BY AGE, RACE/ETHNICTIY, AND SEX  
Massachusetts, 2010-2014 
 
 White, non-Hispanic Black, non-Hispanic Asian, non-Hispanic Hispanic 
Age 
Group 
Males   Females Total Males Females Total Males Females Total Males Females Total 
00-04 607101 579335 1186436 88339 83562 171901 68569 66722 135291 169590 162054 331644 
05-09 661478 632397 1293875 87447 83076 170523 66506 66618 133124 155244 149359 304603 
10-14 725431 690543 1415974 87321 83892 171213 59628 60969 120597 148002 142798 290800 
15-19 826988 806078 1633066 101485 98853 200338 67925 74244 142169 162782 155403 318185 
20-24 834770 837685 1672455 106468 104712 211180 87302 94991 182293 168747 161051 329798 
25-29 811146 817602 1628748 88736 91360 180096 95342 107630 202972 152550 147251 299801 
30-34 734828 746257 1481085 79931 86075 166006 90090 101846 191936 143809 143430 287239 
35-39 705001 726954 1431955 74887 81772 156659 85455 92370 177825 122039 128392 250431 
40-44 840321 875397 1715718 76031 83378 159409 76761 82904 159665 108745 117729 226474 
45-49 968624 1006505 1975129 78763 83135 161898 64351 69346 133697 96706 107037 203743 
50-54 1023251 1068831 2092082 73632 79294 152926 53855 58443 112298 77774 87933 165707 
55-59 939972 998576 1938548 58986 65853 124839 43936 49846 93782 57458 67615 125073 
60-64 809221 880725 1689946 44215 52283 96498 34745 39701 74446 40965 50404 91369 
65-69 615458 691628 1307086 29425 38486 67911 23307 26809 50116 27091 35238 62329 
70-74 417310 502632 919942 19346 27740 47086 17887 20448 38335 17149 24108 41257 
75-79 311707 411392 723099 13185 21294 34479 12666 14505 27171 10667 16501 27168 
80-84 243164 373559 616723 8190 15443 23633 7394 9712 17106 6296 10649 16945 
85+ 224282 485670 709952 6669 15659 22328 5268 8367 13635 5105 9562 14667 
 
 
 
Population Data Source: United States Census Data (2010-2014) 
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Appendix IV 
Racial/Ethnic Breakdown of the Massachusetts and United States Populations* 
       
      Massachusetts (2010-2014) 
 
White, NH
75.0%
Other*
2.7%Hispanic
10.2%
Asian, NH
5.7%
Black, NH
6.4%
 
      United States (2010-2014) 
 
White, NH
62.8%Black, NH
12.2%
Asian, NH
4.9%
Hispanic
16.9%
Other*
3.2%
        
 
Data Source: United States Census Data, 2010-2014 
*Other includes people reporting 2 or more races. 
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